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Abstract 
 
Microtubule instability is a common feature among several neurodegenerative diseases. Abnormal 
genetic or environmental changes induced to tubulin or microtubule-related molecules such as MAPs, 
motor proteins, microtubule +TIPs or even microtubule severing enzymes are associated with reduced 
stability and increased dynamicity of microtubules in degenerating neurons. Microtubules form the main 
tracks that serve intracellular transport of cargos like synaptic proteins, mitochondria and polyribosomes 
covering long distances in neurons. In addition, it is now known that microtubules are important players 
regarding the development and maintenance of dendritic spines. Overall, microtubules have a central 
role keeping neurons in shape concerning their role in neuronal morphology, intracellular transport and 
synaptic plasticity, uncovering the reason why microtubule-related deficiencies are frequent in 
neurodegenerative diseases. Consequently, MTA are used as part of a therapeutic strategy to 
neurodegenerative diseases where they are intended to stabilize degenerating microtubules and prevent 
neuronal loss. Here we characterized the effect of Taxol, Epothilone D and Noscapine as regards to their 
ability to stabilize microtubules, using primary hippocampal cultures. We showed that these drugs are 
able to increase microtubule stability, although with different mechanisms of action, by increasing the 
relative amount of polymerized and acetylated tubulin. Moreover these drugs were capable of inducing 
neurite extension. Finally, we showed that there is a slight decrease in microtubule stability in an in vitro 
tau-aggregation AD model.  
Keywords: Microtubules; Microtubule post-translational modifications; Synaptic plasticity; 
Neurodegenerative diseases; Microtubule-targeting agents. 
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Resumo 
 
A presença de microtúbulos instáveis é um fenómeno recorrente em várias doenças neurodegenerativas. 
Alterações anormais, de origem genética ou ambiental, induzidas na tubulina ou em moléculas 
relacionadas com os microtúbulos tais como MAPs, proteínas motoras, +TIPs dos microtúbulos ou mesmo 
enzimas responsáveis por cortar os microtúbulos, estão associadas com a reduzida estabilidade e 
hiperdinâmica dos microtúbulos em neurónios que degeneram. Os microtúbulos constituem grande parte 
das estruturas responsáveis por apoiar o transporte celular de materiais tais como proteínas da sinapse, 
mitocôndrias e poliribossomas, por vezes durante longas distâncias em neurónios. Além disso, 
recentemente foi descoberto que os microtúbulos são responsáveis também por suportar o 
desenvolvimento e a manutenção de espículas dendríticas. Em conjunto, os microtúbulos têm um papel 
central no que toca à manutenção de neurónios saudáveis tendo em conta o seu papel no suporte da 
morfologia neuronal, no transporte intracelular e na plasticidade sináptica, percebendo-se assim, o 
porquê de alterações anormais nos microtúbulos e proteínas relacionas serem frequentemente 
observáveis em doenças neurodegenerativas. Desta forma, existem compostos que são usados como 
estratégia de terapia em doenças neurodegenerativas com o objectivo de estabilizar microtúbulos 
susceptíveis de degenerar e assim prevenir morte neuronal. Neste projecto caracterizou-se o efeito do 
Taxol, da Epotilona D e da Noscapina tendo em conta a capacidade que estes compostos apresentam em 
estabilizar microtúbulos, usando culturas primárias do hipocampo. Mostrou-se que estes compostos são 
capazes de aumentar a estabilidade dos microtúbulos, apesar de usarem diferentes mecanismos, tendo 
em conta o aumento na quantidade de tubulina polimerizada e acetilada. Além disso, estes compostos 
conseguiram promover o crescimento de neurites. Finalmente, mostrou-se que há um ligeiro decréscimo 
na estabilidade dos microtúbulos num modelo in vitro da doença de Alzheimer baseado na agregação da 
proteína tau. 
Palavras-chave: Microtúbulos, Modificações pós-traducionais em microtúbulos; Plasticidade sináptica; 
Doenças neurodegenerativas; Compostos que interagem com microtúbulos. 
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1.1 Dendritic spines 
 
1.1.1 Structure and function 
Glutamatergic synapses are the major excitatory synapses occurring in the mammalian central nervous 
system. These types of synapses take place at special post-synaptic membrane protrusions named 
dendritic spines. Dendritic spines vary in size (0.5 – 2 μm long), are motile and acquire different sizes and 
shapes, ranging from long, thin filipodia-like protrusions to mushroom-shaped spines: filopodia, thin, 
stubby and mushroom (Goellner and Aberle, 2012) (Figure 1). A typical mushroom spine contains three 
compartments: a bulbous head contacting the axon, a constricted neck in the middle and a delta-shaped 
base at the junction with the dendrite. Conversely, thin spines have longer necks and narrower heads, 
whereas stubby spines lack a neck and are formed by a dense patch of branched actin (Korobova and 
Svitkina, 2010) (Figure 1). The heads of spines contain an Arp2/3 complex-dependent actin branched 
network shaping the volume of the spine head, whereas the spine neck is probably maintained by actin 
filament bundle associated with myosin so it can contract (Korobova and Svitkina, 2010). These are not 
permanent structures but rather reflect a continuum of shapes that dynamically change over time 
(Rochefort and Konnerth, 2012). 
During early synaptogenesis, dendritic shafts (the axis of dendrites) are covered with transient filopodia 
that grow and shrink trying to meet a developing axon. When they find activity-dependent signals, 
synaptogenesis is triggered and filopodia change their shape and undergo maturation (Portera-Cailliau et 
al., 2003). As synapse formation progresses the numerous dendritic filopodia are gradually replaced by 
spines (Matus, 2005). Spine density reaches its maximum level during late development when synaptic 
plasticity is at its height and then decreases to a relatively stable level throughout adulthood in normal 
individuals (Zhang and Benson, 2000). Nonetheless, studies using multiphoton microscopy over days to 
months in living mice have confirmed that spines and their synapses can form and retract throughout 
adulthood (Grutzendler et al., 2002, Trachtenberg et al., 2002) establishing the idea that adult brains can 
retain the capacity to form new synapses and thereby remodel its circuitry throughout life. 
The morphology of spines can directly affect functional communication between neurons (Bourne and 
Harris, 2007, Harms and Dunaevsky, 2007). Enlarged spine heads correlate with an increased size of the 
postsynaptic density (PSD) (Tada and Sheng, 2006), while spine surface area, spine volume, bouton 
volume, and number of presynaptic vesicles are all highly correlated with synaptic area and therefore 
synaptic strength (Harris and Sultan, 1995, Schikorski and Stevens, 1999, Fiala et al., 2002). PSD is a 
compartment where most of the molecular diversity of excitatory synapses is settled and where the 
initial signal transduction events take place in response to presynaptic inputs inducing synaptic work. It is 
directly apposed to the active zone (pre-synaptic terminal) and perfectly matched with it in size and 
shape. Nearly all dendritic spines contain a PSD which is composed of a complex matrix of postsynaptic 
receptors (ionotropic glutamate receptors, G protein-coupled receptors – GPCRs, and tyrosine kinase 
receptors), cell adhesion molecules, scaffolding proteins, signaling molecules and cytoskeletal elements 
involved in synaptic signaling and plasticity, altogether forming a condensed “proteinaceous disk-like 
structure” (Nimchinsky et al., 2002, Sheng and Hoogenraad, 2007). 
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Figure 1 – (From Bourne, J. N., & Harris, K. M., Annual review of neuroscience, 2008) Variability in spine shape and size. A three-
dimensional reconstruction of a hippocampal dendrite (gray) illustrating different spine shapes including mushroom 
(blue), thin (red), stubby (green), and branched (yellow). PSDs (red) also vary in size and shape. 
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Actin filaments are often directly connected with membrane-embedded receptors, thereby linking 
synaptic inputs to structural modifications. In fact, cooperation between actin filaments and microtubules 
is thought to be important in dendritic spine morphology and synaptic plasticity (Hoogenraad and 
Akhmanova, 2010). Consequently, it is believed that synaptic inputs occurring in spines activate receptors 
that in turn may interact with scaffolding proteins, effector proteins (kinases) and/or actin filaments that 
sequentially interact with microtubules that will keep the flow of information necessary for spine 
rearrangement (Priel et al., 2010). The spine neck, on the other hand, seems to restrict this flow of 
information by hampering diffusional exchange of signaling molecules to dendritic spines in the 
neighborhood (Koch and Zador, 1993), localizing biochemical changes to a particular synapse (Bliss and 
Collingridge, 1993). Moreover, the spine neck serves as a barrier to suppress Ca2+ leakage from the spine 
head to the dendritic shaft since Ca2+ is an important activator of synapse-specific regulatory mechanisms 
including cytoskeleton remodeling (Nimchinsky et al., 2002). 
In summary, dentritic spines are small sites spread over dendritic branches that concentrate specific 
proteins needed to receive and transmit information to the soma coming from pre-synaptic terminals of 
connected neurons.  
 
1.1.2 A site of synaptic plasticity 
Synaptic plasticity in the mammalian central nervous system is required to support highly dynamic 
processes such as learning and memory. Although these processes are often considered together, 
learning is considered the process by which the nervous system improves its adaptation to the 
environment, whereas memory represents a process by which this information is stored in neurons or in 
the connections between them (Priel et al., 2010). As previously said, there is a strong correlation 
between the size of the spine and the strength of the synapse, making spine remodeling an attractive 
structural mechanism underlying learning and memory once synaptic strength differences/favored 
synaptic connections between groups of synapses are thought to be the molecular foundation behind 
these processes. It is interesting to think that filopodia may extend and retract when looking for a target 
axon as a correlate to learning – readiness to learn something new while trying to adapt to the 
environment – while spines mature and enlarge preserving and favoring specific signals – information 
stored. The idea that adaptations within the intraneuronal matrix, rather than or in addition to changes 
to interneuronal connectivity, are involved with learning and memory is consistent with species-specific 
patterns of connective plasticity. That is, human pyramidal neurons were proven to have more extensive 
dendrite arbors and spine densities compared to mouse pyramidal neurons (Benavides-Piccione et al., 
2002) and accordingly possess more extensive intraneuronal cytoskeletal matrices (Priel et al., 2010). 
Moreover, spatial learning (Moser et al., 1997) and exposure to enriched environments (Kozorovitskiy et 
al., 2005) alter hippocampal spine numbers and lead to improvements in the performance during several 
learning tasks (Bruel-Jungerman et al., 2005). Experience plays an important role eliminating excessive 
and imprecise synaptic connections formed early during development but is also responsible for the 
formation of new ones (Lichtman and Colman, 2000, Zuo et al., 2005). So, it is clear that synaptic 
plasticity is correlated with alterations to dendritic spines (number, size, shape or composition) where 
cytoskeleton elements play an important role. However, because synapses undergo rapid changes in 
response to environmental perturbations, it is unknown how dynamic synaptic circuits maintain indelible 
memories for a lifetime. With that in mind, one group recently showed that two populations of stable 
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spines are important for maintaining lifelong memories: (1) a small fraction of new spines induced by 
novel experience together with (2) spines formed early during development that remain after experience-
dependent pruning represent a unique and stable physical entity for lifelong memory storage (Yang et al., 
2009) (Figure 2). 
 
Figure 2 – (From Yang, G., et al, Nature, 2009) Schematic summary of spine remodeling and maintenance throughout life. 
After birth there is a great production of spines while some are eliminated right after during development due to 
neuronal connections refinement. Spines that survive are stable throughout life. New experiences are responsible 
for the formation of new spines as well as for pruning already existing spines that survived developmental pruning. 
Different experiences are responsible for the accumulation of a specific set of spines during life, and thus, despite 
dynamic plasticity, dendritic spines can provide a structural basis for learning and memory storage.  
 
Memory is seen as a physical substrate, as something substantive and concrete. As such, a convincing 
molecular correlate for memory is the reorganization of the cytoskeleton within spines, as already 
mentioned specifically microtubules and actin filaments, responsible not only to connect structures in the 
cell body to synapses allowing the exchange of important building blocks, trophic signals and cellular 
waste but also to adapt and maintain the spine conformation according to the input received. Structural 
changes in the cytoskeleton that supports both pre and post-synaptic terminals are accompanied by an 
increase or decrease in synaptic strength, consequently, they potentiate/decrease the release of 
neurotransmitters or favor/hamper activation of certain synaptic contacts over others, respectively (Priel 
et al., 2010, Dent et al., 2011). Besides, it is known that large spine heads are generally stable, express 
large numbers of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) and 
contribute to strong synaptic connections. By contrast, spines with small heads are more motile, less 
stable, and contribute to weak synaptic connections (Matsuzaki et al., 2004, Holtmaat et al., 2006). 
Synaptic plasticity occurring in dendritic spines is bidirectional, that is, accompanied by enlargement or 
shrinkage of the spine head, as a result of an input frequency-dependent shift in the F-actin/G-actin 
equilibrium (Okamoto et al., 2004). As already stated, this capacity may be the molecular basis of 
memory and learning processes since it has been suggested that large spines represent “memory spines” 
and small spines represent “learning spines” (Kasai et al., 2003). Moreover, there is an overwhelming 
amount of evidence showing that synapses are plastic and undergo short- and long-term modifications 
during developmental refinement of neural circuits in learning and memory (Kandel, 1997, Malenka and 
Bear, 2004, Flavell and Greenberg, 2008). Long-term potentiation (LTP) is the best characterized form of 
such plasticity, which is observed at excitatory synapses in the CA1 region of the hippocampus (Nicoll and 
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Malenka, 1995). Indeed, there is a large amount of literature documenting the enlargement of spine 
heads as well as the emergence of new spines after the induction of LTP, whereas spine shrinkage and 
elimination are considered to be a key step in long-term depression (LTD) (Matsuzaki et al., 2004, Nagerl 
et al., 2004, Okamoto et al., 2004, Zhou et al., 2004). Interestingly, changes in synaptic strength and spine 
morphology share common early steps, including activation of N-Methyl-D-aspartate receptors 
(NMDARs) and calcineurin in the case of LTD, but diverge in later steps, with phosphoprotein 
phosphatase 1 activity required for LTD but not for spine shrinkage. The latter is mediated by cofilin 
activity (protein that triggers F-actin depolymerization) (Zhou et al., 2004), further supporting the idea of 
an association between synaptic plasticity and dendritic spine morphology remodeling, at least in the first 
steps. Besides, modifications in the number and activity of membrane surface neurotransmitter receptors 
are considered to be a key event underlying synaptic modification in dentritic spines. For example, the 
intracellular domain of AMPARs is phosphorylated to increase ion conductance during early LTP (Benke et 
al., 1998). To generate a long-lasting LTP, however, it is necessary to increase the number of postsynaptic 
glutamate receptors on the postsynaptic surface. These postsynaptic changes appear to be reversed 
during LTD, including dephosphorylation of AMPARs and their removal from the postsynaptic membrane 
(Gu and Zheng, 2009). Also, blocking AMPARs exocytosis prevents the induction of LTP, whereas blocking 
endocytosis prevents the induction of LTD (Bredt and Nicoll, 2003). 
Individual synapses exhibit site-specific plasticity, which, in its long-term form, requires somatic 
transcripton and translation as well as local protein synthesis (Martin et al., 1997, Kandel, 2001). Early LTP 
is short-lasting and requires post-translational modifications of synaptic proteins but is independent of 
protein synthesis, while late LTP represents the long-lasting phase of LTP that is both transcriptional and 
translational dependent (Voronin et al., 1995, Reymann and Frey, 2007). Thus, in order to establish late 
LTP and LTD it is required that specific material is transported to specific synapses – the “synaptic tag and 
capture” hypothesis. This hypothesis postulates that modifications activated synapses include the 
formation of a molecular “tag” that can facilitate the capture of specific material being delivered 
throughout the dendritic arbors to dendritic spines (Frey and Morris, 1998, Redondo and Morris, 2011). 
This process is possible due to the active transport of gene products that require three critical 
components such as cytoskeletal tracks (formed by microtubules and actin), molecular motors (kinesin, 
dynein, and myosin), and cargos (Liu et al., 2012). In fact, in addition to transcriptional activation in the 
nucleus and local protein synthesis at the synapse, the coordinated upregulation of kinesin-mediated 
transport is also a critical component for long-term learning-related plasticity (Puthanveettil et al., 2008). 
According to this view, proteins carried by kinesins in an anterograde fashion are used to induce 
immediate synaptic changes while mRNAs are subsequently used to maintain these changes. 
In summary, synaptic plasticity is thought to be crucial supporting unique brain skills as learning and 
memory, and remodeling of the cytoskeleton is of extreme importance to this plastic phenomena. 
Therefore, a better understanding of the molecular and cellular mechanisms underlying synaptic 
plasticity is of great value to understand brain development and function under both physiological and 
pathological conditions. 
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1.2 The role of cytoskeleton in synaptic plasticity 
 
1.2.1 Microtubules 
 
1.2.1.1 Structure and function in neurons 
Microtubules are formed from the association of dimers of α- and β-tubulin into protofilaments; 13 
protofilaments further interact side by side to make up a hollow tube. The head to tail association of α- β 
heterodimers is responsible for the microtubule intrinsic polarity, where the plus end (or faster growing 
end) shows a β monomer while the minus end (or slow growing end) shows an α monomer. In vivo, 
proteins such as γ-tubulin bind to the minus ends of microtubules promoting nucleation of tubulin dimers 
but also capping this terminals leaving the plus ends responsible for microtubule elongation (Zheng et al., 
1995). Each tubulin dimer has two GTP molecules non-covalently bound, one in each monomer, but 
however, only one is exchangeable with free GTP, the one in β-tubulin. The presence of GTP enhances 
the polymerization process, however, hydrolysis of GTP to GDP by an intrinsic β-tubulin GTPase domain 
occurs subsequently to microtubule polymerization (Carlier et al., 1989). The fast addition of GTP-bound 
tubulin dimers to microtubules is responsible for the formation of a GTP cap in the plus end where GTP 
molecules from β-tubulin remain with three phosphate groups promoting stabilization of the straight 
conformation in protofilaments, and consequently, microtubule growth is induced. Loss of the cap results 
in the transition from growth to shrinkage (catastrophe), whereas reacquisition of the GTP cap results in a 
transition from shortening to growth (rescue). This characteristic dynamic behavior, termed “dynamic 
instability”, allows a rapid remodeling of microtubules (Mitchison and Kirschner, 1984). GPCRs are 
thought to regulate this dynamics in vivo by mobilizing G protein (Gα and/or Gβγ) subunits to bind to 
microtubules. In addition, receptor-independent activators of G proteins signaling also mediate a diverse 
range of signals within the cell responsible for rearranging the microtubule network. This dynamic ability 
of microtubules to quickly polymerize and depolymerize are critically involved in cell division and 
differentiation, cell motility, intracellular transport, cell morphology, and recently it is known that in 
neurons it may also support synaptic plasticity (Desai and Mitchison, 1997, Roychowdhury and Rasenick, 
2008). Microtubules are key determinants of neuronal polarity (Kapitein and Hoogenraad, 2011) and 
form the transport highways for cargo trafficking in axons and dendrites in neurons (Hirokawa and 
Takemura, 2005). They show intracellular variations in their density, orientation and post-translational 
modifications (PTMs) but also in their interacting partners such as motor proteins, microtubule associated 
proteins (MAPs), severing enzymes and microtubule plus-end tracking proteins (+TIPs). As further 
explored below, the occurrence of different sets of microtubules and binding partners is what confer 
neuronal polarity and assure the transport of cargoes to specific subcellular compartments present in 
such extensive and polarized cells as neurons including growth cones and dendritic spines (Kapitein and 
Hoogenraad, 2011). 
 
1.2.1.2 Microtubule post-translational modifications 
MAPs bind to microtubules and regulate their stability and function by modifying their interaction with 
motors proteins as well as other important proteins involved in transport and cytoskeleton 
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rearrangement (Liu et al., 2012). Besides MAPs, direct enzymatic modifications on α- and β-tubulin are 
also thought to alter microtubule stability and function: microtubule PTMs. These modifications are 
capable of generating different sets of microtubules and consequently different microtubule-associated 
functions by altering the way microtubule polymers can interact with proteins complexes that regulate 
specific cellular processes. Microtubule PTMs occur in already polymerized tubulin. Mature, long-lived 
microtubules accumulate more modifications as compared to dynamic microtubules (Westermann and 
Weber, 2003, Hammond et al., 2008), so, microtubule PTMs are normally associated with stable 
microtubules, but they do not promote microtubule stabilization per se, at least directly (Baas and 
Ahmad, 2013). However, some PTMs are thought to further increase microtubule stability by reducing 
the activity of microtubule depolymerases (Peris et al., 2009). There are several microtubule PTMs known 
(Hammond et al., 2008, Janke and Kneussel, 2010, Janke and Bulinski, 2011) divided into two groups: 
mono-modifications and poli-modifications. Mono-modifications include detyrosination, acetylation and 
phosphorylation, while glutamylation and glycylation are part of poli-modifications (Figure 3). 
Detyrosination is the process by which a tyrosine residue in the C-terminal of α-tubulin is removed 
(Ikegami and Setou, 2010). This tyrosine can be replaced (retyrosination) after the tubulin dimer is 
removed from the microtubule lattice by the action of tubulin tyrosine ligase. Freshly polymerized tubulin 
dimers are tyrosinated in the α-tubulin subunits by default, allowing for dynamic microtubules to be 
detected by making use of antibodies against tyrosinated α-tubulin. The detyrosinated/tyrosinated 
tubulin state can alter the interaction of microtubules with molecular motors and +TIPs. Accordingly, 
tyrosinated microtubules are more prone to recruit +TIPs (Infante et al., 2000, Peris et al., 2006), and thus 
regarded as dynamic microtubules, since microtubule +TIPs are responsible to promote microtubule 
growing/shrinking. In their turn, detyrosinated microtubules (more stable microtubules) are enriched in 
axons (Hammond et al., 2008) and interestingly have more affinity for kinesin-1 (Dunn et al., 2008, 
Konishi and Setou, 2009). This suggests that microtubule PTMs can influence intracellular cargo transport 
and sorting (Kapitein and Hoogenraad, 2011). Although it is known that detyrosinated tubulin is present 
mainly in axons, recent work showed that the turnover of microtubules in axons and dendrites is similar 
(similar stability). Probably, microtubule lifetime is not the predominant cause for the axonal enrichment 
of detyrosinated microtubules, and instead the activity or concentration of modifying enzymes differ 
between these two compartments (Hammond et al., 2010). Glutamylation and glycylation involve the 
addition of short or long chains of glutamate and glycine aminoacids, respectively, into glutamate 
residues in the C-terminal of both α- and β-tubulin. These poli-modifications in the C-terminal tail of both 
tubulin monomers may be responsible of tagging microtubules and also alter the way they interact with 
proteins, like severing proteins, MAPs and motor proteins (Larcher et al., 1996, Bonnet et al., 2001), thus 
influencing microtubule function. Acetylation, the addition of an acetyl group on lysine 40 of α-tubulin, is 
common in microtubules and can be found on long-lived, stable microtubules (Hammond et al., 2008). 
This modification as well can be responsible for structural alterations in microtubules and consequently 
change their role in cellular processes like cargo transport, as kinesin-1 binds with higher affinity to 
acetylated microtubules in vitro (Reed et al., 2006). In summary, tubulin PTMs can influence microtubules 
by regulating their stability and/or structure, and the recruitment of microtubule interacting proteins 
such as MAPs, molecular motors, +TIPs, severing proteins and other proteins that may in the future show 
a relevant role in microtubule dynamics regulation. The occurrence of a diverse set of microtubule PTMs 
and their complex combinations form different patterns of PTMs, leading to the hypothesis that cells 
possess a “tubulin code” (Westermann and Weber, 2003, Verhey and Gaertig, 2007) or a “microtubule 
code” (Janke and Kneussel, 2010) that can guide cell effectors to operate on specific locations, regarding 
that different cell compartments have different subsets of microtubules (Janke and Kneussel, 2010). 
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Figure 3 – (From Janke, C. et Bulinski, J. C., Nat Rev Mol Cell Biol, 2011) Schematic representation of α- and β-tubulin post-
translational modifications. Carboxy-terminal tails of both subunits are represented as amino acid sequences. 
Both α-tubulin and β-tubulin can be modified by polyglutamylation and polyglycylation on different Glutamate 
residues within those tails. Together with detyrosination at the C terminus of α-tubulin, these modifications are 
specific to the C-terminal tails of tubulin. Acetylation of Lysine 40 is localized at the amino-terminal domain of α-
tubulin. 
 
Both spatial and temporal differential composition of microtubules could promote specific cargos to be 
transported to specific sites at specific time points, for example. Indeed, it was shown that synaptic 
activity can regulate tubulin PTMs changing the set of proteins targeted to neurites (Maas et al., 2009). 
This could be the case also for spines, where activity-dependent modifications in microtubules could 
recruit a restrict group of proteins to be delivered into dendritic spines and be of great importance in 
synaptic plasticity. 
 
1.2.1.3 Microtubules support synaptic plasticity 
In developing neurons, actin filaments and microtubules act together to guide and support the growth 
and differentiation of axons and dendrites. In contrast to these well-studied examples of microtubule-
actin cooperativity, it is widely accepted that in dendrites of mature neurons the two cytoskeletal 
domains are spatially separated; while actin filaments are predominately concentrated in spines, stable 
microtubules are confined to the dendritic shaft and do not branch off into spines. Accordingly, studies 
examining mature dissociated hippocampal neurons have suggested that microtubules cannot enter in 
dendritic spines (Kaech et al., 1997, Kaech et al., 2001), but recent reports (Gu et al., 2008, Hu et al., 
2008, Mitsuyama et al., 2008, Jaworski et al., 2009) showed the capture of the plus ends of dynamic 
microtubules inside spines. Growing microtubules specifically accumulate a set of factors, the already 
mentioned +TIPs, at their ends. Moreover, they can be used as tools to visualize growing microtubule 
ends even within dense microtubule networks (Jaworski et al., 2009). Among +TIPs, proteins of the EB 
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family directly interact with the majority of other known +TIPs and have been implicated as key 
regulators of microtubule-associated signaling pathways (Akhmanova and Steinmetz, 2010). Importantly, 
in contrast to EGFP-α-tubulin, that incorporates throughout microtubules allowing one to image all 
microtubules within a living neuron, EB3-EGFP labels the fast growing plus ends of polymerizing 
microtubules, but not paused or depolymerizing microtubules (Stepanova et al., 2003) and thus can be 
used to specifically target growing microtubules that may enter in spines. An EB3 binding partner, 
p140Cap, was identified to bind to a Src kinase substrate and F-actin binding protein, cortactin (Jaworski 
et al., 2009) (Figure 4), in spines, demonstrating a possible mechanism of actin-microtubule interaction 
there. The binding ability of EB3 to drebrin may also contribute to the interaction between microtubule 
and actin filaments (Geraldo et al., 2008). The interaction of microtubule plus-ends containing EB3, with 
drebrin and cortactin may therefore represent a link for signaling between microtubules and the actin 
cytoskeleton within dendritic spines, which can be of key importance to understand local changes of 
spine and synapse structure during plasticity. The reason it was thought microtubules in spines were less 
abundant might be due to the fact they are very sensitive to disruption, and very dynamic, so, it was 
supposed that intraspinal microtubules depolymerized during conventional fixation methods once studies 
using microtubule-conserving fixation methods or live experiments were a success showing intraspinal 
microtubules. Westrum and Gary were the first to observe microtubules in spines, associated with the 
PSD, with the aid of enhanced microtubule preservation techniques (Westrum and Gray, 1976). Different 
approaches to track spines by labeling neurons with microtubule-associated protein 2 (MAP2) failed 
(Kaech et al., 2001). This could be due to the fact that MAP2 does not label the dynamic ends of 
microtubules, but rather the more stable sections of microtubules that are present in the dendritic shaft 
(Hu et al., 2008). Thus, it now seems that stable microtubules are predominantly present as bundles in 
dendritic shafts whereas dynamic microtubules can enter dendritic spines. The association of 
microtubules with the PSD before mentioned suggested that microtubules may have a direct role in 
synaptic plasticity and consequent spine remodeling upon activity or the absence of it. Indeed, recent 
studies showed that after LTP-induction on hippocampal slices, microtubules of the dendritic shaft 
ramified into spines that were specific to the stimulated postsynaptic membranes (Mitsuyama et al., 
2008). Moreover, the frequency of microtubules polymerizing into spines was observed to increase after 
activation of synaptic NMDARs, and NMDAR-dependent spine enlargement was dramatically enhanced in 
spines targeted by microtubules (Merriam et al., 2011). Conversely, a study was published showing that 
chemical LTD decreases microtubule dynamics in the dendritic shaft as well as the frequency of 
microtubule spine invasions (Kapitein et al., 2011). Since increases in spine size are known to depend on 
actin polymerization (Okamoto et al., 2004), and now, that microtubule and actin dynamics work hand 
with hand, it is perhaps not surprising that microtubule invasions into spines contribute to spine 
enlargement during LTP. Importantly, inhibition of microtubule dynamics with Nocodazole (drug that 
inhibits microtubule polymerization) markedly inhibited microtubule invasion of spines and abolished the 
increase in spine size that followed synaptic NMDARs activation (Merriam et al., 2011). Another study 
showed that Taxol (drug that stabilizes microtubules) can potentiate the effects of brain-derived 
neurotrophic factor (BDNF) on spine formation, and, on the other hand, Nocodazole completely blocked 
the effect of BDNF (Gu and Zheng, 2009). These findings further suggest that microtubules play an 
important role in spine development and plasticity.  
Furthermore, in an elegant study conducted in living neurons Hu et al. discovered that almost 10% of 
spines were targeted by microtubules per hour in a long term time lapse imaging experiment, indicating 
many spines on a neuron may be targeted by microtubules over a day. In addition, in all types of dendritic 
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protrusions examined (filopodia, stubby spines, thin spines and mushroom-shaped spines) microtubules 
were capable of rapidly extending into and out of the full extent of the protrusion, but did it more 
frequently and for longer periods on mature spines, suggesting that microtubule invasion of spines may 
function to maintain spine structure (Hu et al., 2008). Surprisingly, the same authors discovered that even 
in mature hippocampal and cortical neurons with 63 days in vitro (DIV) microtubules remained dynamic, 
meaning that the ability to extend into spines is probably maintained later in life. It is known that 
dynamic instability enables microtubules to explore different cellular locations for potential interacting 
structures and signaling components. A productive interaction may stabilize this “highway” between two 
distant locations within the cell allowing them to communicate and change important components. 
Indeed, the function microtubules serve by transiently target dendritic spines is likely to involve transport 
of essential proteins into and out of spines, since microtubules are the major long-distance transport 
machinery inside all cells (Liu et al., 2012). Microtubules that reach spines might be biochemically 
“tagged” after a connection is established and perhaps tubulin PTMs may play a role, as previously said. 
This “tagging” could result in the specific kinesin-mediated delivery and/or dynein-mediated removal of 
receptors, structural proteins, mRNA, GTPase effectors or organelles that may be required for synaptic 
development and plasticity (Kneussel and Loebrich, 2007, Jacob et al., 2008, Dent et al., 2011). It is 
interesting to think of spines like isolated cities that rely on a road network (microtubules and actin) so 
that the working class (activity-dependent effector molecules and building blocks) can get into the city 
and do their job (spine remodeling). In fact, polyribosomes were found to be recruited into spines after 
LTP induction (Ostroff et al., 2002). Additionally, microtubules are also involved in vesicle trafficking of 
neurotransmitter receptors and mitochondria to dendritic spines (Gu and Zheng, 2009) (Figure 4). The 
coordinated regulation of axonal transport in pre and post-synaptic neurons has been identified as a 
critical mediator of long-term learning-related plasticity (Puthanveettil et al., 2008) and this idea is 
concordant with Mitsuyama’s lab hypothesis, the “endless memory amplifying circuit”, where they 
propose that retrograde transport of Ca2+/calmodulin-dependent protein kinase IV from spines to the 
nucleus could activate specific transcription factors leading to anterograde products such as AMPARs and 
Ca2+/calmodulin-dependent protein kinase II (CaMKII) to be translocated to stimulated postsynaptic 
membranes (Goellner and Aberle, 2012, Mitsuyama et al., 2012) according to the synapse “tagging” 
theory already mentioned. This group also states that the translocation of proteins to transmit signals 
from stimulated synapses to the nucleus appears as a more appropriate and selective mechanism to form 
memories, in contrast to signal transmission by action potentials and calcium waves that could affect 
adjacent non stimulated synapses as well.  
Thus, microtubules are no longer seen only as important components regarding cell structure 
maintenance and integrity, shaping and allowing transport of cargo along cells, but in addition, as a 
dynamic, plastic structure involved in neuronal polarity (Hoogenraad and Bradke, 2009) and synaptic 
plasticity capable of accumulating modifications that code for specific signals. 
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Figure 4 – (From Gu, J., Zheng J., Q., Open Neurosci J. 2009) A schematic diagram illustrating potential functions of 
microtubules in dendritic spines. In addition to the proposed microtubule regulation of actin filaments through 
p140Cap, Src kinase and cortactin, microtubules may also be involved in delivering membraneous organelles (e.g. 
mitiochondria and receptor-containing vesicles), as well as ribosome/RNA complexes, to the dendritic spine. It is 
likely that microtubules and actin filaments cooperate in the delivery of these cargos into spines and in the 
regulation of spine structure and function. 
 
1.2.2 Actin 
Actin is particularly abundant in axonal growth cones and dendritic spines (Hotulainen and Hoogenraad, 
2010). Within spines, actin is present as a soluble pool of monomeric G-actin and as polymerized F-actin 
filaments that confer the characteristic spine shape. In the presence of Mg2+, K+ or Na+ ions G-actin 
assembles into long, helical F-actin polymers (Frieden, 1983). Long filaments are predominantly present 
in the spine neck while short, branched actin filaments are found in the spine head (Kapitein and 
Hoogenraad, 2011). Like microtubules, actin filaments also have intrinsic polarity: the barbed end (the 
fast-growing end) and the pointed end (slow-growing end) with its ATP binding site exposed; the barbed 
end pointing to the plasma membrane in the presynaptic and postsynaptic regions (Kapitein and 
Hoogenraad, 2011, Liu et al., 2012). Whether ADP or ATP is bound to the actin monomer affects 
polymerization into filaments and their association to actin-binding proteins (Priel et al., 2010). 
Concerning dendritic spines, actin filaments are generally considered as mediators of synapse dynamics 
being the predominant cytoskeletal element there (Fifkova and Delay, 1982). Decoration of actin 
filaments with myosin II confirmed that actin filaments were the major cytoskeletal component of spines 
(Korobova and Svitkina, 2010). Older results had shown that actin filaments in spines are highly dynamic 
and that rapid changes in spine shape and size can be driven by actin (Fischer et al., 1998). Recent results 
concordantly state that spine structure changes through the reorganization of the actin network 
(Matsuzaki et al., 2004, Okamoto et al., 2004, Honkura et al., 2008). In its turn, actin network is regulated 
by GTPases belonging to the Rho family (Martino et al., 2013), a class of hydrolases expressed in 
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eukaryotic cells that includes Rho, Rac, and Cdc42 subfamilies (Etienne-Manneville and Hall, 2002). 
Activation of Rho GTPases produces a substantial increase in spine density on both basal and apical 
dendrites of hippocampal CA1 pyramidal neurons (Martino et al., 2013). Modifications on dendritic spine 
morphology concerning actin rely on specific motor proteins named myosins. Myosins are enriched in the 
PSD, where they translocate along actin filaments regulating their contractility and by this means spine 
shape (Osterweil et al., 2005, Ryu et al., 2006). Live-cell imaging studies in vitro and in vivo have 
established that spines are plastic and undergo activity-dependent changes in morphology, which are 
believed to be controlled by the actin network. Indeed, actin polymerization is coupled with spine 
formation/enlargement during LTP, whereas LTD involves spine shrinkage through actin depolymerization 
(Fukazawa et al., 2003, Okamoto et al., 2004, Zhou et al., 2004). Another study showed that CaMKII, RhoA 
and Cdc42 are activated during LTP, and in particular long-lasting, spine-specific Cdc42 activation plays an 
important role maintaining spine structure for long periods (Korobova and Svitkina, 2010).  
Thus, intraspinal actin and microtubule dynamics are thought to be of extreme importance during spine 
development, changing and maintaining the structure of synapses undergoing LTP or LTD, both known as 
molecular correlates of learning and memory. 
 
1.3 Microtubule instability: an important player in brain diseases 
 
Several neurodegenerative diseases including Alzheimer’s disease (AD), other tauopathies, Parkinson’s 
disease (PD) and Huntington’s disease (HD) are known to display microtubule instability, and 
consequently, defective intracellular transport (Brunden et al., 2009, Sudo and Baas, 2011, Franker and 
Hoogenraad, 2013, Hinckelmann et al., 2013, Millecamps and Julien, 2013, Esteves et al., 2014, Smith et 
al., 2014). In healthy neurons, pre and post-synaptic structures require a functional microtubule network 
capable of a competent intracellular transport work in order to exchange specific material with the 
neuronal soma, sometimes throughout very long distances (Kapitein and Hoogenraad, 2011). This 
particular neuronal demand is important to establish efficient synaptic connectivity and assure overall 
brain functioning, and that is probably why dysfunctional microtubules are a common feature among 
neurodegenerative diseases. Moreover, it is now clear that microtubules have an important role in 
dendritic spine formation and maintenance as already discussed, further highlighting microtubule’s 
importance in neurons.  
Particularly in AD, dendritic spine loss is observed in the hippocampus and throughout the cortex of 
patients (DeKosky and Scheff, 1990, Walsh and Selkoe, 2004, Knobloch and Mansuy, 2008). Such 
alterations are thought to be responsible for cognitive deficits before the absence of neuronal loss. 
Several pieces of evidence, mentioned above in the microtubule section, suggested that spine elongation 
may be caused by microtubule polymerization; conversely, synapse loss or spine loss observed in AD may 
be caused by the depolymerization of intraspinal microtubules (microtubule instability). Indeed, it is 
known that amyloid-β, an hallmark abnormal protein in AD, activates glycogen synthase kinase-3β (GSK-
3β) (Terwel et al., 2008) and the activated form of GSK-3β causes the abnormal hyperphosphorylation of 
tau, consequently leading to depolymerization of axonal microtubules, resulting in the impairment of 
axonal transport (Iqbal et al., 2009). Tau, a major MAP in neurons, plays an important role in the 
outgrowth of neuronal processes and development of neuronal polarity by promoting microtubule 
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assembly and stabilization affecting microtubule dynamics and consequently intracellular transport (Lee 
et al., 2001, Kapitein and Hoogenraad, 2011, Morris et al., 2011). Normal tau is mainly present in the axon 
bound to microtubules, but hyperphophorylated tau has low affinity for microtubules, is prone to 
aggregation into neurofibrillary tangles (NFTs) (Brunden et al., 2009) (Figure 5), and distributes to the 
somatodendritic compartment decreasing the efficiency of axonal transport in neuropathies (Konzack et 
al., 2007). In dendrites, tau aggregates are able to sequester other MAPs (Alonso et al., 1997). In the 
process, disruption of intraspinal microtubules might happen due to the loss of the microtubule-
preserving effect inherent to MAPs (Mitsuyama et al., 2012). Actually, the brains of patients with AD and 
many other central nervous system disorders, such as fronto-temporal lobar degeneration, Pick’s disease, 
corticobasal degeneration and progressive supranuclear palsy, contain inclusions comprised of tau 
(Brunden et al., 2009), suggesting that microtubule instability might be universal among these disorders. 
In addition, it is suggested that amyloid-β is a putative intraspinal microtubule depolymerizer capable of 
inducing spine loss and synaptic dysfunction, ultimately leading to the cognitive deficits associated with 
AD (Mitsuyama et al., 2009, Zempel et al., 2010). Moreover, it is thought that overactivation of a NMDA-
calcineurin-GSK-3β pathway may indicate a mechanism by which synapses degenerate in AD, since 
amyloid-β oligomer-induced spine loss and dendritic dystrophies can be prevented by calcineurin 
inhibition (Wu et al., 2010).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 – (From Brunden, K. et al., Nat Rev Drug Discov., 2009) Tau in healthy neurons (a) and in tauopathies (b).  a - Tau is 
particularly abundant in axons that stabilizes microtubules and regulates the spacing between them. Stable 
microtubules are required to support traffic of cellular cargos along neuronal processes. b - It is thought that tau 
function is compromised in AD and other tauopathies. This probably results from both tau hyperphosphorylation, 
which reduces the binding of tau to microtubules, and the sequestration of hyperphosphorylated tau into NFTs, 
which reduces the amount of tau that is available to bind microtubules. The loss of tau function leads to 
microtubule instability and reduced axonal transport, which could contribute to neuropathology. 
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It is interesting to think that this NMDA-calcineurin-GSK-3β pathway as well as being responsible to 
induce alterations in spine morphology during LTD in normal physiological conditions, may also be 
responsible for spine shrinkage and/or loss when deregulated, like in the case of AD where this pathway 
is overactivated. Finally, in patients with AD, a reduced microtubule density is observed in pyramidal 
neurons compared with age-matched controls, bringing up the concept that drug-induced stabilization of 
microtubules could be beneficial in AD and other tauopathies (Brunden et al., 2009), although the 
traditional microtubule-stabilizing agents (MSA) including taxanes have poor blood-brain barrier (BBB) 
penetration (Ballatore et al., 2007). 
Other neurological disorders as Autism spectrum disorders (ASD) and Schizophrenia are characterized by 
marked disruptions in information processing and cognition, and recent studies support altered synaptic 
connectivity and plasticity in the brains of affected individuals (Glantz and Lewis, 2000, Tackenberg et al., 
2009, Hutsler and Zhang, 2010). In this regard, some schizophrenic and bipolar patients were reported to 
have decreased spine density (Figure 6) in pyramidal cells of temporal and frontal cortex (Garey et al., 
1998). Besides, smaller spines have been reported in the striatum of schizophrenics (Roberts et al., 1996). 
Furthermore, MAP-2 and -3 are found to be abnormally expressed and there is altered phosphorylation 
of MAP1B in schizophrenia (Blanpied and Ehlers, 2004) potentially showing that the microtubule network 
could also be affected and responsible at some point in the disease-causing mechanism. Fragile X brain is 
characterized by an elevated spine density (Figure 6), showing elongated, tortuous spine morphologies 
which are thought to result from pruning deficits (Irwin et al., 2001). Moreover, lack of fragile X mental 
retardation protein has been shown to result in filopodia-like immature spines and altered synaptic 
plasticity in fragile X-syndrome, possibly through the deficient regulation of MAP1B translation (Lu et al., 
2004). In another mental retardation disease, Down syndrome, there is a decrease in the number of 
muschroom-shaped spines (Blanpied and Ehlers, 2004).  
As previously said, microtubule PTMs are emerging as important regulators of microtubule dynamics and 
interaction with MAPs, motor proteins and +TIPs. Thus, deficient microtubule PTMs may also be 
associated with neurological disorders. In fact, depression is associated with increased detyrosination and 
deacetylation, alterations that are thought to lead to spine decrease in size and density (Wong et al., 
2013). Moreover, poli-glutamylation is thought to enhance tau interaction with microtubules in normal 
conditions (Boucher et al., 1994). So, tau binding to microtubules could also be disturbed in AD due to 
deregulated tubulin PTMs, something not studied yet. 
In summary, there are several brain diseases where microtubules are unstable, many due to deficiencies 
in MAPs, and thereby efficient intracellular transport and synaptic plasticity is compromised. As dendritic 
spines are fundamental structures in the brain, it is reasonable to think that a breakdown in any neuronal 
process responsible to fuel or support them can alter normal brain connectivity. Consequently, it is wise 
to take them into account in therapeutic strategies. Specifically, drugs that target microtubules, thereby 
reducing microtubule instability, might be able to restore the normal function of intracellular transport 
and respective support in synaptic plasticity. Accordingly, MSA would aim to promote spine maturation 
and restore spine stability in ASD, fortify existing synapses and restore spine plasticity in schizophrenia, or 
prevent dramatic spine loss in AD (Penzes et al., 2011). So, a role for microtubules in spine development 
and plasticity could open up new windows in the study of the molecular and cellular mechanisms 
underlying several brain disorders. Given that many brain disorders are associated with abnormal spine 
morphology or density, it would be interesting to confirm if microtubules are involved in disease-causing 
mechanisms, and in that case, if microtubule-based therapeutic strategies would be of help. 
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Figure 6 – (From Penzes, P. et al., Nat Neurosci., 2011) This graph relates dendritic spine number versus age, in a normal 
subject (black), in ASD (pink), in schizophrenia (green) and in AD (blue). Bars across the top indicate the period of 
emergence of symptoms and diagnosis. In normal subjects, spine numbers increase before and after birth; spines 
are selectively eliminated during childhood and adolescence to adult levels. In ASD, exaggerated spine formation or 
incomplete pruning may occur in childhood leading to increased spine numbers. In schizophrenia, exaggerated spine 
pruning during late childhood or early adolescence may lead to the emergence of symptoms during these periods. In 
AD, spines are rapidly lost in late adulthood, suggesting perturbed spine maintenance mechanisms that may 
underlie cognitive decline. 
 
1.4 Microtubule-targeting agents 
 
 
1.4.1 What are they? 
Several drugs target α- or β-tubulin, forcing conformational alterations in the tubulin dimer consequently 
altering microtubule structure, the so called microtubule-targeting agents (MTA). Depending on the drug, 
such conformational changes on tubulin can facilitate microtubule assembling, disassembling or even 
stabilize microtubule length within a range (without promoting assembling or disassembling) (Amos, 
2011). These molecules have varied structure, can be natural or synthesized, and are nowadays used in 
several occasions in cancer chemotherapy (Amos, 2011) due to their ability to compromise normal 
microtubule “dynamic instability”, crucial phenomenon in dividing cells. 
Among drugs that promote microtubule assembling, Taxol (also known as Paclitaxel) is probably the most 
famous, belonging to the Taxanes class of MSA. Taxol binds to β-tubulin subunits in a pocket on the 
luminal surface of the microtubule lattice and counteracts the effect of GTP hydrolysis (that would 
facilitate depolymerization) (Amos and Lowe, 1999, Prota et al., 2013). At high concentrations Taxol 
overstabilizes microtubules compromising microtubule dynamics completely, whereas at low 
concentrations it selectively compromises catastrophe events, this way favoring the overall 
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polymerization of microtubules at plus ends (Derry et al., 1995, Derry et al., 1997). Epothilone D is 
another well studied MSA from a different class, the Epothilones. Epothilones bind near the Taxanes site 
on β-tubulin and that is probably why Taxol and Epothilone D have a similar mechanism of action, as both 
promote microtubule assembly and suppress microtubule “dynamic instability” (Kamath and Jordan, 
2003, Perez, 2009). Both drugs bind along the microtubule length, strengthening contacts between 
adjacent tubulin dimers within protofilaments and also by stabilizing lateral contacts between 
protofilaments (Khrapunovich-Baine et al., 2011). At high concentrations, MSA are thought to generate 
new nucleation sites that promote assembling of new microtubules in various directions (De Brabander et 
al., 1981, Masurovsky et al., 1981). 
Differently, Noscapine is a drug that does not promote microtubule assembly or disassembly. This drug is 
known to bind specifically and stoichiometrically to tubulin. Unlike Taxanes and Epothilones, Noscapine 
does not significantly promote microtubule polymerization and does not alter the tubulin 
polymer/monomer ratio. Instead, Noscapine modulates microtubule dynamics by reducing 
growing/shortening rates and increasing the percentage of time that microtubules spend in a steady-
state, thus stabilizing the microtubule length within a range (Landen et al., 2002, Landen et al., 2004). 
Although Noscapine stabilizes microtubules, does it in a distinct way comparing to Taxol and Epothilone D 
(MSA), therefore this drug is considered to be a microtubule-modulating agent (MMA) instead of a MSA. 
Finally, Nocodazole is one well-known example of a microtubule-destabilizing agent (MDA). At high 
concentrations, this drug binds free tubulin monomers and lower their capacity to assemble onto the 
microtubule polymer, thereby shifting the balance between polymer and free tubulin toward 
depolymerization (Baas and Ahmad, 2013). 
 
1.4.2 Microtubule-targeting agents as a therapeutic strategy in neurodegenerative 
diseases 
Considering the major role played by microtubules in intracellular transport and synaptic plasticity, it is 
wise to consider them as a therapeutic target in neurodegenerative diseases where microtubule 
degeneration and subsequent dendritic spine deficiencies lead to a decrease in the number of functional 
synapses. Accordingly, neuropsychiatric disorders presenting cognitive deficits associated with abnormal 
spine density and shape could also benefit from this therapeutic approach.  
One among several of therapeutic strategies on neurodegenerative diseases focuses on MTA (Figure 7). 
MTA have been studied and used for a while in chemotherapy, so, much information is known already for 
some of these drugs. Concerning MSA, high doses are used in chemotherapy and side-effects as 
peripheral neuropathy and neutropenia have been reported (Mielke et al., 2006, Scripture et al., 2006, 
Reyes-Gibby et al., 2009, Bedard et al., 2010). However, low doses of MSA are used in studies regarding 
neurodegenerative diseases. MSA were already tested in in vitro and in vivo models of Amyotrophic 
lateral sclerosis (ALS), PD, HD, AD and other tauopathies (Fanara et al., 2007, Brunden et al., 2010, 
Shemesh and Spira, 2011, Das and Miller, 2012, Zhang et al., 2012, Brunden et al., 2013, Cartelli et al., 
2013). They are intended to stabilize and promote polymerization of existing microtubules in an attempt 
to counteract microtubule degeneration and associated negative effects: disrupted intracellular 
transport, synaptic plasticity and overall neuron morphology. 
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Taxol is a strong MSA used already in neurodegenerative disease models (Zhang et al., 2005, Michaelis et 
al., 2006, Sengottuvel and Fischer, 2011), however it is not suitable for the treatment of diseases of the 
central nervous system since it does not readily cross the BBB (Fellner et al., 2002, Brunden et al., 2012). 
Conversely, Epothilone D is brain penetrant, and was preferred among other MSA of the Epothilones class 
of MSA due to its pharmacokinetic and pharmacodynamic properties (Brunden et al., 2011). Accordingly, 
Epothilone D accumulates in the brain, and this may be an advantage as it might allow for prolonged drug 
activity in the brain, decreased drug doses and treatment frequency and at the same time minimizing 
peripheral exposure (Brunden et al., 2010). Epothilone D, at much lower doses than used in human 
cancer treatment, was able to improve axonal microtubule density and decreased axonal dystrophy in tau 
transgenic mice, leading to an alleviation of cognitive deficits without adverse side effects (Brunden et al., 
2012). Furthermore, Epothilone D showed beneficial effects on synaptic function and behaviour in a 
mouse model of schizophrenia (Andrieux et al., 2006) showing the possibility of using MSA in neurological 
disorders also.   
 
 
 
 
 
 
 
 
 
Figure 7 – (From Brunden, K. et al., Nat Rev Drug Discov., 2009) Schematic illustration of recent strategies to reduce 
neurodegeneration in the case of tauopathies. The use of MSA focuses on the negative effects of tau loss-of-
function. Abnormal hyperphosphorylated tau has low affinity for microtubules and aggregates into NFTs. MSA are 
intended to recover microtubule stability lost in tauopathies due to loss of tau-associated microtubule stabilization. 
Moreover, this strategy could be useful in other neurodegenerative diseases where microtubule instability is 
present. 
 
Although beneficial effects were observed in neurodegenerative disease models with MSA, doubts were 
raised about the negative effects induced by MSA regarding microtubule overstabilization. MSA promote 
abnormal microtubule nucleation and assembly for high concentrations as already mentioned before. 
Moreover, rather than simply stabilizing and condensing microtubules, long-term MSA administration 
induce microtubule polar reconfiguration (Shemesh and Spira, 2010). This is of extreme importance 
because polarization of microtubules and neuronal polarization are parallel events, and interfering with 
the regulation of microtubule stability disrupts proper establishment of neuronal polarity (Witte et al., 
2008). Accordingly, alterations in the microtubule polarity patterns of axons and dendrites could have 
profound negative consequences in the normal operation of intracellular transport and synaptic plasticity 
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(Kapitein and Hoogenraad, 2011, Baas and Mozgova, 2012). This made scientists rethink the therapeutic 
strategy and establish that it would be important to normalize microtubule dynamicity without the 
overstabilization effect (Brunden et al., 2013). Therefore, drugs capable of mildly stabilizing microtubules 
without promoting microtubule polymerization, nucleation of new microtubules or overstabilization are 
now being pursued. MMA seem to suit this profile, as they do not promote microtubule polymerization 
and are able to mildly stabilize microtubule length while reducing overall dynamicity. Noscapine, a MMA, 
is a common antitussive agent, already used in cancer treatment without toxicity (Landen et al., 2002, 
Landen et al., 2004), can be orally administered, has no reported side-effects, crosses the BBB and 
minimally affects normal dividing tissues and peripheral nerves (Landen et al., 2004). This makes 
Noscapine a nice candidate to reduce microtubule instability in neurodegenerative diseases. Actually, 
Noscapine was shown to stabilize hyperdynamic microtubules in an ALS mouse model (Fanara et al., 
2007). 
It is important to know that MTA will not bring back the normal microtubule dynamics, and most likely 
the neuron is not able to fully recuperate from microtubule-related injuries. However, these drugs should 
be able to maintain microtubules stable and prevent severely microtubule degeneration. Furthermore, 
MTA affect the entire microtubule system. So, in the future, one should be able to target specifically 
instable microtubules and promote microtubule stabilization in a more physiological way, without 
compromising microtubules dynamics. Accordingly, strategies focused in microtubule-related proteins 
would be of interest as they should confer specificity to the treatment while targeting natural molecular 
mechanisms responsible for regulation of microtubule dynamics. Turn the focus into molecular targets 
such as the enzymes that affect the microtubule PTMs or the microtubule +TIPs would probably create 
strategies more specific to a set/section of microtubules. In the case of the enzymes responsible for 
microtubule PTMs one should be able to manipulate microtubule stability at a subcompartmental level, 
once these PTMs show a specific pattern regarding cellular localization; while using microtubule +TIPs 
would create the possibility of controlling dynamic microtubules that enter dendritic spines, without 
promoting overstabilization, possibly regulating dendritic spines morphology.  
 
1.5 Experimental goals 
 
The first goal of this project was to characterize the effect of Taxol, Epothilone D (both MSA) and 
Noscapine (MMA) on the microtubule stability of rat primary hippocampal neurons by quantification of 
alterations in microtubule PTMs induced by these drugs. According to the literature, MSA should induce 
accumulation of microtubule PTMs, as would be expected with greater stability. This means that 
microtubules would have a higher concentration of acetylated tubulin and detyrosinated tubulin, and by 
opposition less tyrosinated tubulin (Baas and Ahmad, 2013). However, Taxol and Epothilone D have a 
different mechanism of action comparing to Noscapine, so, different profiles were expected regarding 
their effect on microtubule PTMs. Determining the effect these drugs have on microtubule PTMs would 
allow for future simple screenings of new MTA based on their effect on microtubule PTMs, having in mind 
that good candidates would increase microtubule stability without massively increasing microtubule 
polymerization, induce overstabilization and completely block dynamicity. After, we sought to find the 
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ability of these drugs to promote neurite extension in primary neurons. Finally, we wanted to determine 
the stability of microtubules in an in vitro tau-aggregation AD model by evaluating the PTMs of the 
microtubule network, in an attempt to understand if this would be a good model to test in the future the 
ability of Taxol, Epothilone D and Noscapine to recover microtubule stability. 
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2. Materials and Methods 
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2.1 Materials 
 
2.1.1 Antibodies 
Name Company Catalog number Dilution used 
Anti-acetylated tubulin Sigma Aldrich T-6793 1:10000 
Anti-chicken Alexa 647 Life Technologies A21449 1:500 
Anti-detyrosinated 
tubulin 
Millipore AB3201 1:2500 
Anti-human Tau 10 Homemade  0.5 µg/mL 
Anti-MAP2 Abcam Ab5392 1:10000 
Anti-mouse Cy3 
Jackson Immuno 
Research 
115-165-146 1:200 
Anti-rabbit Alexa 488 Life Technologies A11008 1:200 
Anti-tyrosinated tubulin Sigma Aldrich T-9028 1:2500 
Anti-α tubulin Sigma Aldrich T-6199 1:2500 
Anti-β III Neuronal 
specific tubulin 
Covance PRB-435P 1:2500 
Anti-β tubulin Sigma Aldrich T-4026 1:2500 
ECL anti-mouse IgG 
GE Healthcare 
LifeSciences 
NA9310 1:3000 
ECL anti-rabbit IgG 
GE Healthcare 
LifeSciences 
NA934 1:3000 
 
 
2.1.2 Biological and chemical material 
Name Company Catalog number 
0.5 % Trypsin-EDTA LifeTechnologies 15400 
B-27 serum-free 
supplement LifeTechnologies 17504-044 
Bovine Serum Albumin 
(BSA) 
Sigma Aldrich A4503 
DAPI Life Technologies D1306 
Dimethyl sulfoxide 
(DMSO) 
Merck Millipore 1029311000 
DTT Invitrogen D-1532 
EGTA Sigma Aldrich E4378 
Embryos from pregnant 
Rat (WistarCrl:WI) E18-
19 
Charles River 
Laboratories 2308816 
Epothilone D Johnson&Johnson JNJS 54299076 
Glucose Merck Millipore 1083421000 
Glutaraldehyde Sigma Aldrich G5882 
Hank’s balanced salt 
sodium solution (HBSS) 
[without Ca2+,Mg2+] 
LifeTechnologies 14175 
Heparin Sigma Aldrich H-5284 
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HEPES (liquid) LifeTechnologies 15630-122 
HEPES (powder) Sigma Aldrich H7523 
Horse Serum LifeTechnologies 26050088 
Hydrochloric acid Merck Millipore 1090571000 
L-glutamine LifeTechnologies 25030-024 
Magnesium Cloride Sigma Aldrich M8266 
Minimum Essential 
Medium (MEM) LifeTechnologies 31095-052 
Neurobasal Medium LifeTechnologies 21103-049 
Nocodazole Johnson&Johnson JNJS 1580540 
Normal Goat Serum 
(NGS) 
Sigma Aldrich G9023 
Noscapine Johnson&Johnson JNJS 30396964 
Paraformaldehyde 
(PFA) 
Sigma Aldrich 76240 
PBS 10x Roche Applied Science 11666789001 
Penicilin/Streptomycin LifeTechnologies 15140 
Phosphate Buffered 
Saline (PBS) 
Sigma Aldrich D8537 
PIPES Sigma Aldrich P8203 
Potassium chloride  Merck Millipore 1049380500 
Potassium dihydrogen 
phosphate  Merck Millipore 1048731000 
Sodium acetate Sigma Aldrich S2889 
Sodium bicarbonate  Sigma Aldrich S-5761 
Sodium borohydride Sigma Aldrich 213462 
Sodium chloride  Sigma Aldrich S-9625 
Sodium hydroxide Merck Millipore 1091371000 
SuperSignal West Dura 
Extended Duration 
Substrate 
ThermoScientific 34076 
Taxol Johnson&Johnson 
JNJS 17129515 
JNJS 4795960 
ToxiLightTMbioassay kit Lonza LT07-117 
Triton X-100 Sigma Aldrich T8787 
 
2.1.3 Laboratorial material and equipment 
Name Company Catalog number 
12-Channel Pipettor 5-
50 µL and 50-300 µL 
VWR  
96-well Microplates Greiner BioOne 655906 
Analytical 
Balance 
Sartorius  
Biological Safety 
Cabinet EF/S 
Telstar Clean Air  
Cell Voyager CV 7000 Yokogawa  
Centrifuge Allegra 6 Beckman Coulter 366802 
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Benchtop 
CO2 Incubator Hera cell 
150 
Thermo Scientific 51026281 
Disposable Polystyrene 
Serological Pipets 
 
Fischer-Scientific  
Easy-grip cell culture 
dish, 100x20 mm Corning 353003 
Easy-grip cell culture 
dish, 35x10 mm Corning 353001 
Falcon 15 mL Corning 352196 
Falcon 50 mL Corning 352070 
FIREBOY plus Integra-Biosciences 144000 
FluoroskanAscentTM FL 
MicroplateFluorometer 
and Luminometer 
Thermo Scientific  
IKA MS1 Shaker Sigma Aldrich Z404047 
Leica DMI4000 B Leica Microsystems  
Magnetic Stirrer/Heater IKA 0003622000 
MIAS-2 Multimode 
Microscopy Reader 
Digilab  
Pasteur Pipette Volac D812 
PIPETBOY acu 2 Integra-Biosciences 155000 
Pipette tips Eppendorf  
Pipettes P2, P10, P20, 
P100, P200 and P1000 
Gilson PIPETMAN 
Classic  
Quantum EX Cartridge Millipore QTUM000EX 
Stericup-GP Filter     
0.22 μM 
Millipore SCGPU05RE 
Vi-Cell Counter XR Beckman Coulter 383556 
Zeiss LSM 510 META Zeiss  
 
2.2 Methods 
 
2.2.1 Primary hippocampal cultures 
Pregnant rats (Wistar Crl:WI) at gestational day E18-19 were sacrificed by decapitation and embryos 
collected to petri dishes with pre-warmed HBSS/Hepes buffer (7mM HEPES and 1% Penicillin-
Streptomycin, at 37°C). After all hippocampi were isolated under a dissecting microscope they were 
transferred to a 15mL falcon already with 4.5mL of pre-warmed HBSS/Hepes plus 500µL of 10x 
concentrated trypsin and incubated for 10-15 minutes at 37°C to promote chemical neuronal 
dissociation. Next, 3 washing steps were done using 3-5mL of pre-equilibrated (37°C and 5% CO2) MEM-
Horse medium (10% Horse serum, 0.6% glucose in MEM-medium 1x) before resuspending the 
hippocampi in 3mL of MEM-Horse medium and mechanically dissociate the tissue first with a sterile glass 
Pasteur pipette with a normal tip diameter followed by a similar pipette with a smaller tip diameter. 
Then, cells were centrifuged at 1000 rpm for 5 minutes and resuspended with 2-3mL of MEM-Horse 
medium. Finally, cells were counted using an automatic counter and plated in poly-D-lysine pre-coated 
96-MW microplates with µclear bottom using a cell density of 10 000 or 20 000 cells per well. After 4 
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hours minimum, MEM-Horse medium was replaced by pre-equilibrated Neurobasal medium (2% B27 
supplement and 2mM L-glutamine). 
2.2.2 Transduction of primary hippocampal cultures and addition of pre-formed 
fibrils 
Primary hippocampal cultures plated in poly-D-lysine pre-coated 96-MW microplates with µclear bottom 
using a cell density of 10 000 per well were transduced with Adeno-Associated Virus (AVV) serotype 6 to 
overexpress either human Wild Type (hWT) tau, hP301L tau or Green Fluorescent Protein (GFP), driven by 
the hSYN1 promoter. Appropriate transduction units of virus concerning a multiplicity of infection of 100 
were diluted in Neurobasal medium and directly added to the medium after 3 DIV. A truncated form of 
human tau prone to aggregation containing only the 4 microtubule-binding domains, K18, with a P301L 
point mutation, K18P301L (expressed in bacteria and purified) was provided by Wouter Bruinzeel, 
Tibotec. Furthermore, tau seeds were formed by in vitro fibrilization (Calafate, S., “Tauopathy seeding 
models as a platform for tau aggregation and clearance study”, Master Thesis, University of Coimbra, 
2012) and added at 7 DIV (in addition to transduction). Briefly, 40 μM of K18P301L was mixed with 40 μM 
of heparin and 2 μM of DTT in 100 mM sodium acetate buffer at pH of 7.0. The mix was incubated at 37°C 
for 48 to 72 hours and further centrifuged at 100 000g during 30 minutes at 4°C. The supernatant was 
discarded and the pellet was resuspended in sodium acetate until the desired concentration and then 
stored at -80°C or immediately used. Immediately before use pre-formed fibrils at 40 μM were diluted to 
5 μM with sodium acetate solution and sonicated with a probe tip by 25 pulses, 1 second each pulse with 
10 seconds pause between each. Finally, they were added into the medium at a final concentration of 25 
nM. 
2.2.3 Drug treatment 
Drug powders were resuspended with sterile DMSO under the flow in order to produce stock solutions 
after stored at -20°C with the following concentrations: Taxol 1 mM, Epothilone D, Noscapine and 
Nocodazole 10 mM. The day of treatment (at least 1 day after plating) the final drug concentrations were 
prepared in pre-equilibrated supplemented Neurobasal medium starting from correspondent 100-fold 
concentrated fresh drug solutions previously prepared diluting stock solutions with DMSO (final DMSO 
concentration was always <1%). Afterwards, old medium was replaced by 100 or 200 µL of medium with 
drug treatment depending on how long the neurons would be in culture, less or more than 8 DIV 
respectively. 
2.2.4 Adenylate Kinase toxicity assay 
The cell toxicity assay was performed using ToxiLightTM bioassay kit instructions. Briefly, medium samples 
of 50 µL/well from plated cells treated with Taxol, Epothilone D, Noscapine or Nocodazole (after 1 or 7 
DIV for 24 hours) were collected before fixation for further analysis by In-Cell ELISA. After all reagents 
(including medium samples) were at room temperature (RT) the adenylate kinase (AK) detection reagent 
was reconstituted in assay buffer and incubated for 15 minutes at RT. Then, 25 µL of each sample were 
transferred to 96-MW microplates with µclear bottom and 65 µL of AK detection reagent was added to 
each sample for 5 minutes. Finally, plates were measured using Fluoroskan AscentTM FL  Microplate 
Fluorometer and Luminometer. 
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2.2.5 In-Cell ELISA 
Primary hippocampal neurons were fixed with 0.5% glutaraldehyde/0.5% Triton X-100 in PHEM buffer 
(Schliwa and van Blerkom, 1981) for 10 minutes at RT with an additional permeabilization step with 0.5% 
Triton X-100 in PHEM buffer for 30 minutes. Reduction of background autofluorescence followed using 1 
mg/mL of NaBH4 in PHEM buffer for 10 minutes. Next, neurons were blocked with 5% NGS/0.1% BSA in 
PBS buffer for 30 minutes. Primary antibodies were incubated overnight at 4°C in 1% NGS/0.1% BSA in 
PBS while Horseradish peroxidase (HRP)-attached secondary antibodies were incubated for 1 hour RT in 
0.1% BSA in PBS. There were 3 washing steps using 0.1% BSA in PBS after incubation with primary and 
secondary antibodies, 10 minutes each step. Finally, SuperSignal West Dura Chemiluminescent Substrate 
was used for 5 minutes to develop the signal. Bioluminescence was measured in a microplate 
luminometer.  
2.2.6 Immunocytochemistry 
Primary hippocampal neurons were fixed with 4% PFA in PBS for 10 minutes and washed 2 times with PBS 
for 10 minutes under the hood at RT. Afterwards, permeabilization of neurons was accomplished using 
0.1% Triton X-100 in PBS during 10 minutes followed by a step of washing with PBS for 10 minutes. Next, 
neurons were blocked with 5% NGS/0.1% BSA in PBS for 30 minutes. From this point 0.1% BSA in PBS was 
used as buffer for labeling and washing steps. Primary antibodies were incubated overnight at 4°C. After 
3 washing steps for 10 minutes, secondary antibodies were incubated for 1 hour at RT away from light 
and excess antibody was rinsed. Nuclei were stained using DAPI in 0.1% BSA for 5 minutes. Finally, 
another washing step was done and neurons remained in 0.1% BSA in PBS buffer. Images were obtained 
using Zeiss LSM 510 META confocal microscope or a normal fluorescence microscope Leica DMI4000 B. 
For high content screening purposes automated images were taken using the MIAS-2 Multimode 
Microscopy Reader or the Cell Voyager CV 7000. 
2.2.7 Image Analysis 
To study morphological alterations such as neurite outgrowth, number of neurites and ramification 
points, images from the MIAS-2 Multimode Microscopy Reader and the Cell Voyager CV 7000 were 
analyzed with the Neurite Outgrowth (NEO) assay software from DCI Labs. The 2-channel 2FLUO assay 
was used combining DAPI + β-III Tubulin or DAPI + MAP2 to quantify neurite outgrowth, number of 
neurites and ramification points. 
2.2.8 Statistical Analysis 
Comparison between different sets of data was performed using the Unpaired T-test with Welch’s 
correction or the Two-way ANOVA + Bonferroni post-tests. 
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Part of Figure 8 – For caption please refer to page 34. 
 
3.1 Measurement of cytotoxicity induced by Taxol, Epothilone D, 
Noscapine and Nocodazole 
To check cell toxicity induced by Taxol, Epothilone D, Noscapine and Nocodazole (MTA), a cytotoxicity 
assay was performed in primary hippocampal neurons (cells used in all the experiments). Basically the 
assay measures the amount of AK that leaks into the medium as a result of damage to cell membrane 
integrity consequently reporting possible drug-induced cytotoxicity. After 1 or 7 DIV neurons were 
treated for 24 hours and medium samples collected for the assay before neurons were fixed. There was 
no pronounced toxic effect induced by any drug as toxicity levels did not change much when different 
drug concentrations were compared to the control, from 0.0001 μM up to 10 μM (Figure 8). However, 
Taxol and Epothilone D showed a trend to be toxic after 10 μM as toxicity levels increased approximately 
20% at this concentration. It is important to mention that a positive control (cell membrane destabilizing 
agent like Triton X-100 or stress-inducing agent like hydrogen peroxide) is lacking in order to confirm that 
the assay is working correctly.  
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Figure 8 – Cytotoxicity assay by measurement of AK release of neurons – The toxicity induced by Taxol, Epothilone 
D, Noscapine and Nocodazole was tested in neurons by a bioluminescence method. A- Quantification of the toxicity 
levels normalized to control (mean ± SEM) in neurons treated at 1 DIV for 24 hours; B- Quantification of the toxicity 
levels normalized to control (mean ± SEM) in neurons treated at 7 DIV for 24 hours. Statistical analysis by T-test + 
Welch’s correction, n=2.  
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Figure 9 – Intracellular localization of microtubule PTMs – A, B, Representative images of rat hippocampal 
neurons 7 days in culture labeled for: (A) rabbit anti-β-III tubulin (green) and mouse anti-acetylated tubulin (red), 
white arrows show the absence of acetylated tubulin in dentritic distal sites while the soma and main processes 
including the axon show a yellow labeling due to the overlapping localization of β-III tubulin and acetylated tubulin 
where stable microtubules are; (B) rabbit anti-β-III tubulin (green) and mouse anti-tyrosinated tubulin (red), white 
arrowheads show sites of intense labeling of tyrosinated tubulin including growth cones and tips of dendrites 
where microtubules are predominantly dynamic. Scale bar, 40 μm. 
 
3.2 Intracellular localization of microtubule PTMs 
The goal of this experiment was mainly to determine the intracellular localization of the acetylated and 
tyrosinated tubulin. We confirmed the presence of acetylated tubulin (associated with old, stable 
microtubules) in dendritic shafts as wells as in the axon (Figure 9 A) and interestingly its absence in more 
distal parts of the dendrites (Figure 9 A, arrows), where microtubules with a more dynamic character 
should be present. Tyrosinated tubulin was present in freshly polymerized microtubules, associated with 
dynamic microtubules, mainly in growth cones but also in more distal parts of dendrites (Figure 9 B, 
arrowheads), overlapping with sites where acetylated tubulin was absent.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
β-III tub. Acetylated tub. 
B 
β-III tub. Tyrosinated tub. 
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3.3 Quantification of microtubule PTMs after treatment with MTA 
We quantified changes in the amount of polymerized tubulin as well as in microtubule PTMs induced by 
Taxol, Epothilone D, Noscapine and Nocodazole in neurons by In-Cell ELISA to infer about these drugs’ 
ability to enhance microtubule polymerization and/or stability. Nocodazole is used as a negative control, 
it is known as a microtubule destabilizing agent, the opposite effect of Taxol, Epothilone D and 
Noscapine. Primary hippocampal neurons were treated at different time points, either after 1 or 7 DIV, 
for 24 hours, and then fixed and permeabilized at the same time in order to wash away the non-
polymerized tubulin. This way, we were able to quantify only the polymerized α- or β-tubulin (total 
tubulin) and respective PTMs. 
Neurons treated at 1 DIV for 24 hours by Taxol or Epothilone D increased their relative levels of total 
tubulin (Figure 10 Ai) and acetylated tubulin (in some cases up to more than two times the control) in a 
dose-dependent manner (Figure 10 Aii), although the effect of Epothilone D on the relative levels of total 
tubulin was not statistically significant. Moreover, these drugs induced a significant decrease (almost to 
half the control) in the relative levels of tyrosinated tubulin also in a dose-dependent manner (Figure 10 
Aiii), even though for the two lowest concentrations used there was a trend to increase these 
microtubule PTM. Noscapine was not able to induce an increase in the relative levels of total tubulin 
(Figure 10 Ai). Nevertheless, it induced an increase in the relative levels of acetylated tubulin (Figure 10 
Aii) (not as pronounced as the effect induced by Taxol and Epothilone D) but also in the relative levels of 
tyrosinated tubulin (Figure 10 Aiii). In both cases Noscapine did not show a dose-dependent response like 
Taxol and Epothilone D but instead its effect reached a “plateau” where increasing concentrations of the 
drug did not change the relative levels of acetylated or tyrosinated tubulin, confirming a different 
microtubule-stabilization mechanism of action in comparison to Taxol and Epothilone D. Interestingly, 
Nocodazole, in spite of being a microtubule-depolymerizing agent, slightly increased the relative levels of 
the total, acetylated and tyrosinated tubulin levels for the lowest concentrations used (Figure 10 Ai,ii and 
iii). However, this effect is reversed at higher concentrations where this drug massively decreases the 
relative levels of the total, acetylated and tyrosinated tubulin in a dose-dependent manner as expected. 
Last but not least, the relative levels of detyrosinated tubulin were not altered by any drug for the 
concentrations used (Figure 10 Aiv). Not even Nocodazole, known to destabilize microtubules and 
decrease microtubule length, was able to alter the relative levels of detyrosinated tubulin. 
Neurons treated for 24 hours after 7 DIV were not susceptible to changes in the relative levels of total 
and acetylated tubulin when Taxol, Epothilone D and Noscapine were used (Figure 10 Bi and ii). However, 
Taxol and Epothilone D induced a small decrease in the relative levels of tyrosinated tubulin for 
concentrations higher than 0,03 µM in opposition to Noscapine that did not promote such decrease, 
further confirming a different mechanism of action in comparison to Taxol and Epothilone D (Figure 10 
Biii). Nocodazole, in contrast to the previous drugs, could keep its effect after 7 DIV significantly 
decreasing the relative levels of total, acetylated and tyrosinated tubulin as expected (Figure 10 Bi, ii and 
iii). Here too no drug was able to change the relative levels of detyrosinated tubulin for the 
concentrations used (Figure 10 Biv). 
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Part of Figure 10 – For caption please refer to page 41. 
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Figure 10 – Quantification of the effect induced by Taxol, Epothilone D, Noscapine and Nocodazole on 
microtubule PTMs – Primary hippocampal neurons were treated for 24 hours after 1 (A) or 7 DIV (B) and  the 
effect induced by these drugs on polymerized tubulin and some tubulin PTMs was quantified by  In-Cell ELISA. A, B 
i, ii, iii and iv are groups of graphs showing the quantification of the levels of total tubulin (α- or β-tubulin) (i), 
acetylated tubulin (ii), tyrosinated tubulin (iii) and detyrosinated tubulin (iv) normalized to the respective controls 
(mean ± SEM) for the respective treatment time points. Taxol, Epothilone D and Noscapine can induce alterations 
in microtubule PTMs in neurons at 1 DIV, increasing the relative levels of acetylated tubulin and suggesting that 
these drugs indeed promote microtubule stabilization. However, that effect is lost when the treatment is done 
after 7 DIV. Interestingly, Taxol and Epothilone D showed a similar profile regarding their effect on microtubule 
PTMs, confirming that these drugs share a similar mechanism of action, but different from the mechanism of 
Noscapine, that exhibited a different profile (did not induce an increase on the relative levels of total tubulin not 
even a decrease in the tyrosinated tubulin). Conversely, Nocodazole exerted its effect after 1 and 7 DIV, 
decreasing the relative levels of the total, acetylated and tyrosinated tubulin but interestingly, did not change the 
relative levels of detyrosinated tubulin probably due to the resistance of the population of microtubules or 
microtubule portion bearing this PTM to this drug. Statistical analysis by T-test + Welch’s correction, n=2 or 3. 
 
3.4 Characterization of the effect of MTA on neuronal morphology 
 
3.4.1 MTA effect on neurite length, number and ramification points 
In order to study the effect of Taxol, Epothilone D and Noscapine on neuronal morphology, primary 
hippocampal neurons were either treated at 1 DIV and fixed at 7 DIV or treated at 7 DIV and fixed at 14 
DIV. The reason for the long treatment duration was to be sure drugs could induce significant changes in 
neuronal morphology since similar experiments with treatments lasting just 1 or 3 days did not show any 
effect (data not shown). Moreover, the drug concentration range used was broader for Taxol and 
Epothilone D (0.01nM to 1μM) compared to Noscapine and Nocodazole (0.001 μM to 1 μM) because the 
first drugs showed toxicity for higher concentrations, observed by loss of positive nuclei (which are nuclei 
- DAPI positive - included in a soma attached to neurites - β-III Tubulin positive - a specific neuronal 
marker).  After fixation neurons were labeled for β-III Tubulin and DAPI to track neurites and nuclei, 
respectively (for examples see Figure 11 Ai and Bi). Software that can automatically analyze neurite 
length, number and branching points was subsequently used (Figure 11 Aii,iii and Bii,iii) (NEO, DCI Labs). 
Neurons treated at 1 DIV and fixed at 7 DIV with Taxol and Epothilone D showed a moderate increase in 
neurite length/pos. nucleus and in the number of branches/pos. nucleus when 1 nM of compound was 
used (Figure 12 A). Higher concentrations induced a decrease in the number of pos. nuclei meaning that 
neurons started to suffer drug-related toxicity and died. Noscapine was also able to increase the neurite 
length/pos. nucleus and the number of branches/pos. nucleus (Figure 12 A), although to a lesser extent, 
and at higher concentrations (10 to 1000 times higher) comparing to Taxol and Epothilone D. This means 
that Taxol and Epothilone D are more powerful regarding the analyzed parameters, but Noscapine is 
better tolerated by neurons since there was no drug-related toxicity seen for the concentrations used (no 
decrease in positive nuclei, neurite length or neurite number).  
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Figure 11 – Example of measurement of neurite length, number of neurites and branching by a high-content 
screening approach  – A, B, Representative images of non-treated rat hippocampal neurons (control condition) 
fixed after 7 DIV  (A) or after 14 DIV (B). Ai and Bi: neurons labeled for β-III tubulin (green) and DAPI (blue). Images 
taken with a 20x objective, each image represents a tile. Aii and Bii: a set of sixteen tiles for the same condition are 
acquired by the microscope and then juxtaposed and analyzed by the software NEO, DCI Labs. Aiii and Biii: 
expanded images of Aii or Bii, respectively. The software tracks the nuclei and separates “negative” nuclei (pink 
circles) from “positive” nuclei (red circles). Nuclei (stained with DAPI) overlapping with cell bodies connected with 
neurites (stained with anti-β-III tubulin) are classified as being “positive” nuclei and most likely belong to neurons. 
Other nuclei are classified as being “negative”. Neuronal somas are surrounded by green circles and neurites 
tracked in blue. 
 
Neurons treated at 7 DIV for 7 days respond differently. Taxol and Epothilone D could not induce an 
increase in neurite length/pos. nucleus, number of neurites/pos. nucleus or number of branches/pos. 
nucleus and instead provoked the opposite effect for high concentrations (Figure 12 B). It might be that 
the number of positive nuclei decreases due to drug-related toxicity for concentrations >1 nM, and 
consequently, the total neurite length decreases also as less neurons are present. 
 
 
 
 
 
  
B 
i) ii) iii) 
A 
i) ii) iii) 
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Figure 12 – For caption please refer to page 44. 
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Figure 12 – Quantification of neurite length, number of neurites and branching alterations induced by Taxol, 
Epothilone D, Noscapine and Nocodazole by a high-content screening approach – Primary hippocampal neurons 
were either treated after 1 DIV for 6 days (A) or after 7 DIV for 7 days (B). Several images were acquired with a 20x 
objective in an automated microscope and the effect induced by these drugs on neuronal morphology alterations 
was analyzed by the software NEO as previously mentioned. A, B: graphs showing the quantification of neuronal 
morphology alterations induced by the above mentioned drugs, normalized to the respective controls (mean ± 
SEM) for the respective treatment time points. Taxol, Epothilone D and Noscapine induced a moderate increase in 
the neurite length/pos. nucleus and in the number of branches/pos. nucleus when neurons were treated after 1 
DIV for 6 days, although Noscapine was used in higher concentrations. This effect is lost for neurons treated at 7 
DIV for 7 days. Nocodazole was able to decrease the neurite length/pos. nucleus, the number of neurites/pos. 
nucleus and the number of branches/pos. nucleus in both treatment time points. Statistical analysis by Two-way 
ANOVA + Bonferroni post-tests, n=3. 
 
 
Noscapine was also incapable of promoting neurite length extension or branching when administered 
after 7 DIV (Figure 12 B), however, it did not induce toxicity for the drug concentration range used, 
contrary to Taxol and Epothilone D, as already observed when treatment started at 1 DIV (Figure 12 A). 
Nocodazole decreased neurite length/pos. nucleus, the number of neurites/pos. nucleus and the number 
of branches/pos. nucleus for the higher concentrations used in both treatments starting at 1 or 7 DIV 
during 6 or 7 days respectively (Figure 12 A and B).  
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Figure 13 – Example of measurement of dendrite length, number of dendrites and branching by a high-content 
screening approach  – A, B, Representative images of non-treated rat hippocampal neurons (control condition) fixed 
after 7 DIV  (A) or after 14 DIV (B). Ai and Bi: neurons labeled for MAP2 (red) and DAPI (blue). Images taken with a 
20x objective, each image represents a tile. Aii and Bii: a set of four tiles for the same condition are acquired by the 
microscope and then analyzed by the software NEO, DCI Labs. Aiii and Biii: expanded images of Aii or Bii, 
respectively. The software tracks the nuclei and separates “negative” nuclei (pink circles) from “positive” nuclei (red 
circles). Nuclei (stained with DAPI) overlapping with cell bodies connected with dendrites (stained with anti-MAP2) 
are classified as being “positive” nuclei and most likely belong to neurons. Other nuclei are classified as being 
“negative”. Neuronal somas are surrounded by green circles and dendrites tracked in blue. Scale bar, 400 μm. 
 
3.4.2 MTA effect on dendrites length, number and ramification points 
Here we used the same approach as in the previous experiment except with one alteration: MAP2, a 
specific dendritic marker, was used instead of β-III Tubulin so one could track dendrites instead of all 
neurites (for examples see Figure 13 Ai and Bi). This way, morphological parameters analyzed concern 
dendrites only (Figure 13 Aii, iii and Bii, iii). Maximum concentration used for Taxol and Epothilone D was 
10 nM due to observed toxicity in the previous experiment for higher concentrations. Noscapine and 
Nocodazole were used with the same concentrations as previously. 
 
 
 
 
  
A 
i) ii) iii) 
B 
i) ii) iii) 
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Neurons treated at 1 DIV with Taxol, Epothilone D and Noscapine and fixed at 7 DIV did not show any 
alterations induced by these drugs regarding dendrite length/pos. nucleus, the number of dendrites/pos. 
nucleus or the number of branches/pos. nucleus (Figure 14 A). Strangely, Taxol and Epothilone D at 10 
nM (maximum concentration used for these drugs) abruptly increased both dendrite length/pos. nucleus 
and the number of branches/pos. nucleus to over two times the control.  
Neurons treated at 7 DIV and fixed at 14 DIV showed a moderate increase in the dendrite length/pos. 
nucleus and in the number of branches/pos. nucleus when treated with low concentrations of either 
Taxol or Epothilone D (Figure 14 B). Noscapine was able to promote an increase in dendrite length/pos. 
nucleus, in the number of branches/pos. nucleus but also in the number of dendrites/pos. nuclei, 
although higher concentrations of this drug were used compared to Taxol and Epothilone D as already 
mentioned (Figure 14 B).  
Finally, Nocodazole as expected induced a decrease in dendrite length/pos. nucleus, in the number of 
dendrites/pos. nucleus and in the number of branches/pos. nucleus, both when treatment started after 1 
DIV or 7 DIV, for 6 or 7 days respectively (Figure 14 A and B). 
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Figure 14 – For caption please refer to page 48. 
 
A-Neurons treated at 1 DIV and fixed at 7 DIV 
B-Neurons treated at 7 DIV and fixed at 14 DIV 
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3.5 Characterization of microtubule PTMs in an AD in vitro model 
Here, we made use of In-Cell ELISA to quantitatively analyze microtubule PTMs in a tau-aggregation AD in 
vitro model aiming to understand if microtubule stability is compromised. Primary hippocampal neurons 
were virally transduced at 3 DIV with GFP (control) or human mutated P301L tau. At 7 DIV, pre-formed 
fibrils of K18P301L (truncated form of human tau containing only the 4 microtubule-binding domains, 
K18, with a P301L point mutation, K18P301L, prone to aggregation) were added to part of hP301L tau 
transduced neurons, while others remained without pre-formed tau fibrils. By 14 DIV all neurons were 
fixed and analyzed (AD in vitro model established in primary hippocampal neurons according to Calafate, 
S., “Tauopathy seeding models as a platform for tau aggregation and clearance study”, Master Thesis, 
University of Coimbra, 2012). The addition of pre-formed tau fibrils possibly attracts free non-
microtubule bound tau further promoting aggregation of hP301L tau and, by this means, should leave 
microtubules vulnerable to depolymerization and decrease microtubule stability (not tested before), as 
tau is an important MAP known to stabilize microtubules. In parallel, neurons where also transduced with 
GFP (control) or human WT tau at 3 DIV and fixed at 14 DIV without the addition of pre-formed tau fibrils. 
The overexpression of hWT tau should increase microtubule stability in opposition to the combined effect 
of hP301L tau with pre-formed tau fibrils. 
Transduction of rat primary hippocampal neurons with hWT tau or hP301L tau increased human total tau 
expression levels by ~4 or ~6 times, respectively, compared to controls (Figure 15 A). Unexpectedly, 
neurons transduced with hWT tau did not show significant changes in the relative levels of total, 
acetylated or tyrosinated tubulin (Figure 15 Bi) suggesting absence of microtubule overstabilization effect 
by hWT tau overexpression. Neurons transduced with hP301L tau without pre-formed tau fibrils added 
also did not show variations regarding the relative levels of total, acetylated or tyrosinated tubulin (Figure 
15 Bii). However, neurons with pre-formed tau fibrils added besides hP301L tau transduction showed a 
slight decrease (not statistically significant) in the relative levels of total and acetylated tubulin (Figure 15 
Bii), suggesting that microtubules stability could be affected. 
 
 
 
 
Figure 14 – Quantification of dendrite length, number of dendrites and branching alterations induced by Taxol, 
Epothilone D, Noscapine and Nocodazole by a high-content screening approach – Primary hippocampal neurons 
were either treated after 1 DIV for 6 days (A) or after 7 DIV for 7 days (B). Several images were acquired with a 20x 
objective in an automated microscope and the effect induced by these drugs on neuronal morphology alterations 
was analyzed by the software NEO. A,B: graphs showing the quantification of neuronal morphology alterations 
induced by the above mentioned drugs, normalized to the respective controls (mean ± SEM) for the respective 
treatment time points. Interestingly, here, in opposition to the previous experiment, where both axons and 
dendrites were assessed at the same time, Taxol, Epothilone D and Noscapine induced a moderate increase in the 
dendrite length/pos. nucleus and in the number of branches/pos. nucleus only when neurons were treated after 7 
DIV for 7 days. Nocodazole, again as expected, decreased the dendrite length/pos. nucleus, the number of 
dendrites/pos. nucleus and the number of branches/pos. nucleus in both treatment time points. Statistical analysis 
by Two-way ANOVA + Bonferroni post-tests, n=2. 
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Figure 15 – Quantification of microtubule PTMs alterations in a tau-aggregation Alzheimer’s disease in vitro 
model – Hippocampal neurons transduced with hP301L tau and with pre-formed tau fibrils added or not after 
transduction were fixed at 14 DIV. In parallel, neurons were transduced with hWT tau and fixed at 14 DIV. After 
fixation, the relative levels of total polymerized tubulin as well as of acetylated and tyrosinated tubulin were 
quantified by In-Cell ELISA as previously, in order to infer about microtubule stability. A – Graphs showing the 
quantification of the total human tau relative levels after transduction (n=1). Expression of hWT tau and hP301L 
tau is working as the relative levels of human total tau increase ~4 and ~6 times respectively. B – Quantification of 
microtubule PTMs (mean ± SEM) in the case of overexpression of hWT tau (n=2) (i) and in a tau-aggregation AD in 
vitro model (n=2) (ii). Neurons transduced with hWT tau did not show significant changes in the relative levels of 
total, acetylated or tyrosinated tubulin (absence of microtubule overstabilization), while neurons transduced with 
hP301L tau and pre-formed tau fibrils added showed a slight decrease in the relative levels of total and acetylated 
tubulin suggesting that microtubule stability decreased also. Statistical analysis by Two-way ANOVA + Bonferroni 
post-tests. 
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4.1 Discussion 
 
Several neurodegenerative diseases (Brunden et al., 2009, Sudo and Baas, 2011, Franker and 
Hoogenraad, 2013, Hinckelmann et al., 2013, Millecamps and Julien, 2013, Esteves et al., 2014, Smith et 
al., 2014) are known to report microtubule instability and consequent neurite degeneration. 
Microtubules are essential to neurons as they support intracellular transport of a vast number of 
different cargos to places spread all over the extensive neuronal area (Kapitein and Hoogenraad, 2011). 
Furthermore, it was recently discovered that microtubules have an important role regarding the 
development and maintenance of dendritic spines and therefore, contribute to the proper functioning of 
synaptic connectivity (Gu and Zheng, 2009, Jaworski et al., 2009). This reinforces the importance of 
microtubules in neurons and shows why these particular cells are vulnerable to microtubule instability. 
For that reason, it is important to study microtubule stability in neurodegenerative diseases in order to 
deepen our knowledge on possible disease-inducing mechanisms, always having in mind new valuable 
therapeutic targets. Particularly in AD and other tauopathies, Tau, a MAP, is compromised and is not able 
to fulfill one of its main functions: to organize and stabilize microtubules (Brunden et al., 2009). 
Therefore, the use of MTA to compensate for tau loss-of-function has been a hot topic among AD 
therapeutic strategies. Additionally, microtubule PTMs are known to generally occur in tubulin 
polymerized long enough to accumulate PTMs. Therefore, modified microtubules are associated with 
long-lived microtubules, generally considered stable (Hammond et al., 2008, Baas and Ahmad, 2013). For 
that reason, one way of studying microtubule stability is by looking at their PTMs.  
First, we showed the presence of acetylated tubulin, associated with stable microtubules, in axons but 
also in dendritic shafts, except for their most distal parts. Interestingly, and by opposition, tyrosinated 
tubulin, freshly polymerized tubulin associated with dynamic microtubules, was shown to be present in 
growth cones but also in the extremities of dendrites. 
Additionally, here we showed that Taxol, Epothilone D and Noscapine, all MTA, have the ability to 
increase the relative levels of polymerized tubulin as well as the relative levels of the acetylated tubulin. 
In addition, these drugs induced changes in neuronal morphology by boosting neurite extension and 
ramification during initial stages of neuronal development.  Furthermore a tau-aggregation AD in vitro 
model showed a slight decrease in the total amount of polymerized tubulin but also in the acetylated 
tubulin. This means that microtubule stability was compromised and that, probably, Taxol, Epothilone D 
or Noscapine could revert this effect. 
 
4.1.1 Acetylated tubulin localizes to axons and dendritic shafts in opposition to 
tyrosinated tubulin, mainly present in growth cones and dendritic tips 
Microtubule PTMs are not equally distributed along the neuronal microtubule network but instead show 
a specific pattern where microtubules from different subcellular compartments have different PTMs 
types and levels (Verhey and Gaertig, 2007, Janke and Kneussel, 2010). This pattern is thought to have an 
important role regarding the sorting of cargos from the soma to distant places in the neuron (Janke and 
Kneussel 2010). The presence of stable microtubules in axons and dendritic shafts as in opposition to the 
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presence of dynamic microtubules in growth cones and distal parts of the dendrites (Kollins et al., 2009) is 
in agreement with the function microtubules support in these subcellular compartments. It makes sense 
that in axons and dendritic shafts microtubules are stable to preserve the transport tracks that 
intracellular transport rely on, sometimes to deliver cargos to distant sites in the neuron (Kapitein and 
Hoogenraad, 2011). Whereas dynamic microtubules, with high growing/shrinking rates, are able to 
support axon guidance in growth cones but also deliver the plasticity needed by dendritic spines 
regarding their morphology when trying to find pre-synaptic terminals in order to establish and maintain 
synaptic connections (Tanaka et al., 1995, Jaworski et al., 2009, Kapitein et al., 2010). 
       
4.1.2 Changes in microtubule PTMs induced by Taxol, Epothilone D and Noscapine 
during initial stages of neuronal development suggest a microtubule-
stabilizing effect 
MTA bind to the microtubule lattice consequently changing its conformation. This interaction is capable 
of facilitating polymerization, depolymerization or even stabilization of the microtubule polymer length 
within a certain range, depending on the agent. Furthermore it is known that microtubule PTMs 
concentrate in long-lived microtubules, probably because they are more time exposed to the enzymes 
responsible for PTMs, comparing to recently polymerized microtubules (Hammond et al., 2010). So, one 
way of looking into the overall microtubule network stability in a cell is by quantifying its microtubule 
PTMs.  
Only neurons treated at 1 DIV by MSA were susceptible to alterations to the total polymerized tubulin or 
PTMs. Probably, because at this age neurons are in the beginning of the differentiation process, are more 
“plastic” and so more prone to drug-induced alterations in microtubule PTMs or morphology. As we 
confirmed, Taxol, Epothilone D and Noscapine promote microtubule stabilization reported by the 
increase in the relative levels of acetylated tubulin. However, they do it by different mechanisms. It is 
known that Taxol and Epothilone D bind tubulin monomers and are able to promote microtubule 
polymerization from already existent polymers or even the nucleation of new microtubules, here 
confirmed by the increase in the relative levels of the total polymerized tubulin. Conversely, Noscapine 
binds already polymerized tubulin, stabilizes microtubule length within a certain range without facilitating 
polymerization or depolymerization. Accordingly, it was unable to promote tubulin polymerization, 
confirmed by the absence of an increase in the relative levels of total polymerized tubulin. However, 
there was a moderate increase induced by Noscapine in the relative levels of acetylated tubulin, probably 
due to the prolonged exposure of these microtubules to the modifying enzyme responsible for tubulin 
acetylation, as Noscapine stabilized microtubule length. Furthermore, the difference between these 
drugs is further accentuated regarding the effect on the relative levels of tyrosinated tubulin (recently 
polymerized tubulin): Taxol and Epothilone D decrease them, while Noscapine does not change these 
levels. This suggests that Taxol and Epothilone D stabilize microtubules at the expense of a negative effect 
on dynamic microtubules for high concentrations (overstabilization), while Noscapine just keeps the 
microtubules in a steady-state (does not promote polymerization nor depolymerization) and therefore 
dynamic instability of microtubules is conserved. This overall difference in microtubule-related effects 
induced by Taxol and Epothilone D in comparison to Noscapine could be useful for future drug screening 
purposes regarding MTA: an increase in the total and acetylated tubulin in a dose-response manner while 
at the same time decreasing the tyrosinated tubulin could identify drugs with a Taxol-like mechanism. 
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Differently, an increase in the acetylated tubulin in a non dose-response manner without increasing total 
tubulin nor decreasing tyrosinated tubulin could help identify drugs with a Noscapine-like mechanism. 
The separation of Taxol-like drugs and Noscapine-like drugs could be important in the selection of MTA 
because Noscapine did not show toxic effect for high concentrations used comparing to Taxol and 
Epothilone D, probably because tubulin polymerization is not exacerbated and dynamic microtubules are 
conserved with Noscapine.  
Interestingly, the effect of Taxol and Epothilone D in the relative levels of total, acetylated and 
tyrosinated tubulin showed a dose-dependent response, while Noscapine effect reached a “plateau” 
regarding the moderate increase in the relative levels of acetylated tubulin. It makes sense that, as Taxol 
and Epothilone D bind tubulin monomers and promote polymerization, increasing molecules of these 
drugs induce a proportional increase in the polymerized tubulin (and consequently in the acetylated 
tubulin as more tubulin is prone to be acetylated), as long as free tubulin is available. Noscapine binds the 
already polymerized tubulin in a different tubulin site, favoring the dynamic steady-state of microtubules 
and does not promote polymerization (Landen et al., 2002, Landen et al., 2004). Therefore, it makes 
sense that increasing concentrations of Noscapine do not proportionally increase the relative levels of 
acetylated tubulin once microtubule length remains more or less the same. 
In neurons treated only at 7 DIV, Taxol, Epothilone D and Noscapine could not show any significant effect. 
In order to make sure it was not a technical problem as the signal could be saturated (no difference 
between values for different drug concentrations) due to the use of incorrect antibody dilutions, we 
checked the effect of Taxol regarding total, acetylated and tyrosinated tubulin for treatments starting at 
1, 3 or 7 DIV with higher dilutions of the respective antibodies. We observed that the effect induced by 
Taxol at 1 DIV, decreases at 3 DIV and completely fades away at 7 DIV (data not shown). Therefore, the 
reason why Taxol, Epothilone D and Noscapine are not capable of inducing their effect after 7 DIV is 
probably biological and not due to experiment-related technical issues. It is possible that at that age 
neurons cannot be easily forced to change their microtubule network as they are already mature and less 
“plastic”. This is in accordance with the fact that at 7 DIV only Nocodazole (microtubule-depolymerizing 
drug) is capable of showing its negative effects, decreasing the total, acetylated, and tyrosinated tubulin. 
Finally, no drug used here was capable of inducing an effect in the relative levels of detyrosinated tubulin, 
not even Nocodazole, confirming the existence of a population of microtubules resistant to Nocodazole 
(Conde and Caceres, 2009). In agreement, detyrosinated tubulin is known to be found in the stable 
microtubules (Hammond et al., 2008, Hammond et al., 2010). However, if Taxol, Epothilone D and 
Noscapine were proved to enhance microtubule stability, for example increasing acetylated tubulin, why 
cannot they increase the levels of detyrosinated tubulin? It is possible that this PTM occurs only in a 
defined space along microtubules, and the increase in length and stability of microtubules by these drugs 
does not influence the intensity of its occurrence as it did with acetylated tubulin (Hammond et al., 2010). 
Moreover, this PTM probably localizes to microtubule positions far away from the growing tip, once 
Nocodazole, although capable of decreasing the total amount of polymerized tubulin, did not decrease 
the relative levels of detyrosinated tubulin, demonstrating as a result that this microtubule PTM is 
resistant to Nocodazole action. 
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4.1.3 Taxol, Epothilone D and Noscapine induce morphological changes in initial 
stages of neuronal development 
Taxol and Epothilone D were able to increase the relative levels of polymerized tubulin as well as the 
relative levels of the acetylated tubulin, associated with stable microtubules. Noscapine could also 
increase the relative levels of acetylated tubulin although not so robustly as the previous drugs. Here, we 
tried to understand if these drugs were capable of inducing neurite outgrowth, as wells as formation of 
new neurites and branching of existing ones by a high-content screening approach, once they were able 
to induce microtubule polymerization and or stabilization, important processes for neurons to develop 
(Sakakibara et al., 2013). 
We observed that the MTA induced a moderate increase in neurite length/pos. nucleus and in the 
number of branches/pos. nucleus in neurons treated at 1 DIV but not the ones treated at 7 DIV. These 
results are consistent with the In-Cell ELISA quantifications of microtubule PTM where treatments after 7 
DIV with the same drugs were unable to increase the relative levels of the total, acetylated and 
tyrosinated tubulin. Accordingly, it seems like neuronal microtubules can be forced to polymerize, and 
neurites induced to extend and branch at 1 DIV, but not at 7 DIV, probably because, as already discussed, 
at this stage of development neurons start to differentiate and be less “plastic”, consolidating their 
morphology and so do not respond to drug treatment, where only toxic concentrations promote the 
already stated negative effects (Chuckowree and Vickers, 2003). Also, inhibitory contacts between 
neurons as the neuronal network becomes bigger could hinder further neurite extension. Differently, 
microtubules can serve as a substrate for Nocodazole at both 1 and 7 DIV as expected, since 
depolymerization is possible as long as microtubules are present, and consequently neurites retract due 
to microtubule instability. Importantly, Taxol and Epothilone D exhibited a similar profile regarding their 
effect on the morphological parameters studied, as already did for the effects in microtubule PTM. 
Until this point, we sought to find out the influence of Taxol, Epothilone D and Noscapine on neurite 
outgrowth and branching. We used β-III Tubulin to label microtubules all over the neuron with the 
purpose of tracking neurites, including both dendrites and axons. This approach (using β-III Tubulin as a 
marker) is useful to get general morphological information of the neuron. However, information 
regarding specific neuronal subcompartments such as dendrites and axons is not given separately. These 
two subcompartments are morphologically different, where axons normally extend for bigger distances 
and only one axon exists per neuron, while on the other hand several dendrites are normally present per 
neuron and they are more branched than the axon. Besides, microtubule polarity is different between 
these two compartments: in axons the majority of microtubules have the growing plus-end oriented 
towards the growth cone while in dendrites microtubules present mixed polarity (Baas and Lin, 2011). 
With that in mind we tried to understand if dendrites alone could be affected by the same drugs using 
MAP2 as a marker of neurites instead of β-III Tubulin, as this MAP is mainly present in dendrites. 
Intriguingly, the results of this experiment were the reverse of the previous experiment: here drugs were 
able to induce an effect after 7 DIV but not after 1 DIV. This could mean that only after 7 DIV dendrites 
are prone to morphological changes facilitated by these drugs, and probably this effect was diluted by the 
absence of effect in axons after 7 DIV in the first experiment, using β-III Tubulin (axons cover bigger 
distances than dendrites representing a higher percentage of the total neurite length). In conclusion, 
considering the fact that in the experiment with β-III Tubulin these drugs could only show their effect 
when treatment started after 1 DIV, it could be that axons are more prone to morphological changes 
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after 1 DIV during initial stages of development and dendrites after 7 DIV, when neurons are already in 
mid stages of development. 
 
4.1.4 Tau-aggregation AD in vitro model shows a moderate decrease in 
microtubule stability 
On one hand, we expected the overexpression of hWT tau in neurons to induce microtubule stabilization 
reported by an increase in the total and acetylated tubulin relative levels. On the other hand, we 
expected the opposite effect to be observed when hP301L tau is overexpressed and pre-formed tau fibrils 
added once hP301L tau is mutated in the microtubule-binding domain, which reduces tau affinity for 
microtubules (Guo and Lee, 2011), thereby probably destabilizing microtubules. In addition, pre-formed 
tau fibrils are able to attract both exogenous and endogenous tau further promoting tau loss-of-function 
(Guo and Lee, 2011, 2013). 
Although the overexpression of hWT tau resulted in an increment of the exogenous protein by ~4 times, 
microtubule stability remained unchanged, suggested by the lack of effect on the total, acetylated or 
tyrosinated tubulin. Interestingly, as transduction is done at 3 DIV, and exogenous protein peak 
expression in the neuron occurs only at 7 DIV, it could be that, as suggested before for neurons treated at 
7 DIV with Taxol and Epothilone D, by this age neurons cannot be forced to further stabilize their 
microtubule network or extend their axons beyond a limit. In opposition, it should be possible to 
destabilize microtubules and induce neurite retraction. However, neurons transduced with hP301L tau 
alone did not report any alterations to microtubule stability neither. In this case, it could be that 
endogenous functional rat tau is able to compensate for dysfunctional hP301L tau, maintaining 
microtubule integrity. Conversely, the neuronal microtubule network could be destabilized when the 
combined effect of hP301L tau transduction and pre-formed tau fibrils addition was applied to neurons 
and as a decreasing trend in the relative levels of total polymerized tubulin and acetylated tubulin was 
observed. It is possible that added pre-formed tau fibrils attracted not only hWT tau but also normal 
endogenous tau, thereby affecting microtubule stability. In another scenario, the presence of pre-formed 
tau fibrils could simply provoke physical disturbance, or promote a neuronal stress response, thereby 
affecting the normal structure and function of microtubules.   
 
4.2 Conclusion 
Overall, the results shown here encourage the use of MTA to tackle microtubule-related deficiencies in 
neurodegenerative diseases. Taxol, Epothilone D, and Noscapine, known MTA, increased the levels of 
polymerized tubulin as well as acetylated tubulin in primary hippocampal neurons. Moreover, these drugs 
could also induce changes in neuronal morphology increasing neurite length and branching. Importantly, 
they did so by different mechanisms where Noscapine did not show toxicity for the concentrations used 
unlike Taxol or Epothilone D, and thus, Noscapine-like drugs (MMA) should be highly considered 
regarding microtubule-stabilization focused therapies in neurodegenerative disease. Additionally, the 
tau-aggregation AD in vitro model used here displayed modest microtubule instability by showing a slight 
decrease in the levels of total and acetylated tubulin. An interesting next step would be to analyze 
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neuronal morphology, as we did here, but instead of normal neurons, using this model. Moreover, it is 
known that dendritic spine numbers decrease in AD (Penzes et al., 2011) and by direct consequence 
synaptic function is compromised too. So, it would also be interesting to quantify the number of synapses 
and respective morphology in the same model. Actually, we started to optimize a protocol to 
automatically quantify synapses in normal neurons, using synapsin as a synaptic marker, with same 
software used here to analyze neuronal morphology. However, still many rearrangements are needed to 
improve the quality of the analysis. Finally, the ultimate goal is to use MTA in diseased neurons and try to 
understand if they can revert negative effects like microtubule instability, neurite degeneration and 
synaptic loss. However, other AD in vitro models presenting a more pronounced damage to microtubules, 
and reported damage to synapses, could be used in the future in order to validate the effect induced by 
these or other MTA (Wagner et al., 1996, Qiang et al., 2006, Stoppelkamp et al., 2011, Zempel and 
Mandelkow, 2012). 
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